<!DOCTYPE html><html><head><meta charset="utf-8"><title>2023 sabcs poster | Medlish</title><meta name="viewport" content="width=device-width,initial-scale=1,shrink-to-fit=no"><meta name="description" content="(PS01-01) Feasibility and oncological safety of targeted axillary dissection or sentinel lymph node biopsy in patients with clinically node-positive disease after neoadjuvant chemotherapy in the prosp"><meta property="og:type" content="article"><meta property="og:title" content="2023 sabcs poster"><meta property="og:url" content="https://en.medlish.eu.org/2023/12/07/2023-sabcs-poster/index.html"><meta property="og:site_name" content="Medlish"><meta property="og:description" content="(PS01-01) Feasibility and oncological safety of targeted axillary dissection or sentinel lymph node biopsy in patients with clinically node-positive disease after neoadjuvant chemotherapy in the prosp"><meta property="og:locale" content="zh_CN"><meta property="article:published_time" content="2023-12-07T08:11:04.000Z"><meta property="article:modified_time" content="2023-12-07T08:13:23.124Z"><meta property="article:author" content="Lucas Fu"><meta name="twitter:card" content="summary"><link rel="alternate" href="/atom.xml" title="Medlish" type="application/atom+xml"><link rel="shortcut icon" href="/favicon.png"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/typeface-source-code-pro@0.0.71/index.min.css"><link rel="stylesheet" href="/css/style.css"><link rel="stylesheet" href="/fancybox/jquery.fancybox.min.css"><meta name="generator" content="Hexo 6.3.0"></head><body><div id="container"><div id="wrap"><header id="header"><div id="banner"></div><div id="header-outer" class="outer"><div id="header-title" class="inner"><h1 id="logo-wrap"><a href="/" id="logo">Medlish</a></h1></div><div id="header-inner" class="inner"><nav id="main-nav"><a id="main-nav-toggle" class="nav-icon"><span class="fa fa-bars"></span></a> <a class="main-nav-link" href="/">Home</a> <a class="main-nav-link" href="/archives">Archives</a></nav><nav id="sub-nav"><a class="nav-icon" href="/atom.xml" title="RSS 订阅"><span class="fa fa-rss"></span></a> <a class="nav-icon nav-search-btn" title="搜索"><span class="fa fa-search"></span></a></nav><div id="search-form-wrap"><form action="//google.com/search" method="get" accept-charset="UTF-8" class="search-form"><input type="search" name="q" class="search-form-input" placeholder="搜索"><button type="submit" class="search-form-submit">&#xF002;</button><input type="hidden" name="sitesearch" value="https://en.medlish.eu.org"></form></div></div></div></header><div class="outer"><section id="main"><article id="post-2023-sabcs-poster" class="h-entry article article-type-post" itemprop="blogPost" itemscope itemtype="https://schema.org/BlogPosting"><div class="article-meta"><a href="/2023/12/07/2023-sabcs-poster/" class="article-date"><time class="dt-published" datetime="2023-12-07T08:11:04.000Z" itemprop="datePublished">2023-12-07</time></a><div class="article-category"><a class="article-category-link" href="/categories/2023SABCS/">2023SABCS</a></div></div><div class="article-inner"><header class="article-header"><h1 class="p-name article-title" itemprop="headline name">2023 sabcs poster</h1></header><div class="e-content article-entry" itemprop="articleBody"><p><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568217-4000px.png">(PS01-01) Feasibility and oncological safety of targeted axillary dissection or sentinel lymph node biopsy in patients with clinically node-positive disease after neoadjuvant chemotherapy in the prospective MF-1803 NEOSENTITURK-study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568252-4000px.png">(PS01-02) Long-term outcomes of sentinel lymph node biopsy following neoadjuvant chemotherapy for initially node-positive breast cancer: A systematic review and meta-analysis.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568212-4000px.png">(PS01-03) What to expect from the No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS] trial (KBCSG-21): Clinicopathologic characteristics and axillary lymph node status of enrolled patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568225-4000px.png">(PS01-04) To dissect or not to dissect? The surgeonâs perspective on the prediction of â?4 axillary lymph node metastasis in cN0 T1-2 breast cancer: A comparative analysis of the per-protocol population of the SINODAR-ONE clinical trial.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568251-4000px.png">(PS01-06) The relationship between margin status of &lt; 2mm and local recurrence in DCIS patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568194-4000px.png">(PS01-07) Impact of Race and Ethnicity on Recurrence Risk in Patients with Ductal Carcinoma in Situ Treated with Breast-Conserving Surgery</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568249-4000px.png">(PS01-09) Early Results of a Phase I Pre-Operative Single Fraction Ablative Trial for Early Stage Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571174-4000px.png">(PS01-10) Surgical margins in breast conserving surgery (BCS) for ductal carcinoma in-situ (DCIS) and clinical outcomes: significant associations with increased recurrence and overall survival.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568135-4000px.png">(PS02-01) Efficacy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568152-4000px.png">(PS02-02) Patient-reported outcomes from the Phase 3 CAPItello-291 trial investigating capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR-positive&#x2F;HER2-negative advanced breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568201-4000px.png">(PS02-03) Is de-escalation of treatment by omission of radiotherapy associated with fear of cancer recurrence and health-related quality of life in women with early breast cancer? An exploratory study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568198-4000px.png">(PS02-04) Associations of sleep health with quality of life among women with newly diagnosed breast cancer: baseline results from the AMBER cohort study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568161-4000px.png">(PS02-05) Trajectories and predictors of peripheral neuropathy after neoadjuvant chemotherapy in a prospective cohort of 11</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568229-4000px.png">(PS02-07) Effectiveness of 24-week mobile application based human coaching program for controlling weight</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568214-4000px.png">(PS02-08) The Effect of a Digital Health Coaching Program on Patient Reported Outcomes of Women with Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568151-4000px.png">(PS02-09) Nurse-led individualized follow-up versus regular physician-led visits after early breast cancer (MyHealth) - a randomized</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568181-4000px.png">(PS03-01) Single cell analysis of paired lymph nodes and primary tumors in breast cancer patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568159-4000px.png">(PS03-02) Single-cell metabolic profiling uncovers new precision immunotherapy strategy in triple-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568204-4000px.png">(PS03-03) The spatially resolved single-cell atlas of the tumor immune architecture revealed the central role of IFN-alpha and plasmacytoid dendritic cells in triple-negative breast cancer in the Mayo Clinic cohort and FinXX trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568144-4000px.png">(PS03-04) Tumor immune microenvironment modulates resistance to estrogen suppression in ER+ breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568125-4000px.png">(PS03-06) Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: saving costs and time (the CONFIDENT-B trial)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568167-4000px.png">(PS03-07) Morphometric signature identifies ductal carcinoma in situ of the breast with low risk of progression to invasive breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568226-4000px.png">(PS03-08) Spatial biomechanics determines fate in breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568241-4000px.png">(PS03-09) Age-related normal breast tissue features differ in women with germline BRCA1&#x2F;2 mutations</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568120-4000px.png">(PS04-01) Clinical impact of timing of systemic therapy in patients with early triple negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568155-4000px.png">(PS04-02) BRCA testing and PARP inhibitor utilization in real-world HER2-negative metastatic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568190-4000px.png">(PS04-03) Survival benefit of regional nodal irradiation in clinically node-positive breast cancer following neoadjuvant chemotherapy and breast-conserving surgery</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568176-4000px.png">(PS04-04) Adverse effects (AEs) reported via Patient Reported Outcome Measures (PROMs): A longitudinal analysis of the IMPORT HIGH breast radiotherapy trial (CRUK&#x2F;06&#x2F;003)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568193-4000px.png">(PS04-06) Breast cancer recurrence among women with pre-diagnostic major depression and co-existing substance abuse disorder: A retrospective study in the United States Veterans Health Administration Cohort</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568121-4000px.png">(PS04-07) Associations between Virtual Care Access and Psychological and Mental Health Conditions among Adults with Breast Cancer in the US: A Population-Based Analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568195-4000px.png">(PS04-08) Sociodemographic Risk Factors and Prediction of Aromatase Inhibitor Non-Adherence in Women with Breast Cancer Enrolled in SWOG S1105</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568169-4000px.png">(PS04-09) Patient-Reported Benefit of Resources Designed to Assist with the Financial Toxicity of Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568253-4000px.png">(PS05-01) Accuracy and safety of fibroblast activation protein inhibitor (FAPI) PET&#x2F;CT in diagnosis of axillary lymph node metastasis in early breast cancer patients: a prospective cohort study (PFB-01&amp;02 study)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568254-4000px.png">(PS05-02) PET Imaging of PARP Expression as a Biomarker of Response to Chemotherapy in Breast Cancer: A Nonrandomized Clinical Trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568142-4000px.png">(PS05-03) MagSenseÂ® HER2</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568172-4000px.png">(PS05-04) [89Zr]Trastuzumab-PET&#x2F;MRI to Characterize HER2+ Breast Cancer: A Quantitative Approach on Tumor Heterogeneity</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568202-4000px.png">(PS05-06) Outcomes of Surveillance using Contrast Enhanced Mammography in Women with a Personal History of Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568189-4000px.png">(PS05-07) Early prediction of response to Neoadjuvant Immunotherapy in Triple Negative Breast Cancer (TNBC) with DCE-MRI</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568117-4000px.png">(PS05-08) Restriction Spectrum Imaging MRI for automated evaluation of response to neoadjuvant therapy in breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568192-4000px.png">(PS05-09) A single-arm Phase II clinical study of fulvestrant combined with chemotherapy in the neoadjuvant treatment of HR+&#x2F;HER2- locally advanced breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568178-4000px.png">(PS06-01) Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR+</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568208-4000px.png">(PS06-02) Circulating tumor DNA (ctDNA) monitoring of estrogen receptor-positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568243-4000px.png">(PS06-03) Differences in ctDNA genomic profiles and outcomes of Black and White patients with metastatic breast cancer: results from a large multicenter consortium</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568118-4000px.png">(PS06-04) The prognostic and predictive impact of circulating tumour DNA (ctDNA) dynamics in patients with metastatic Triple Negative Breast Cancer (TNBC) on olaparib based therapy: Results from Cohort E of the PlasmaMATCH trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568216-4000px.png">(PS06-06) Analysis of ctDNA for the detection of minimal residual disease (MRD) using a tissue-free</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568239-4000px.png">(PS06-07) Liquid biopsy determination of HER2 status in breast cancer: results from a novel epigenomic platform</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568206-4000px.png">(PS06-08) Longitudinal Neoadjuvant and Post-operative Evaluation of Circulating Tumor DNA in Early Breast Cancer using a Tumor-Informed Assay: Updated Analysis of the TRACER Cohort</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568234-4000px.png">(PS06-09) Fragmentomic analysis of a circulating tumor DNA targeted cancer gene panel discriminates ER status in metastatic breast cancer liquid biopsies.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568175-4000px.png">(PS07-01) Exemestane and breast cancer prevention: how low can we go? Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative dosing regimen.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568128-4000px.png">(PS07-02) Benign breast disease and microcalcifications in percutaneous biopsies and breast cancer risk</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568184-4000px.png">(PS07-03) Randomized trials of oestrogen-alone and breast cancer incidence: a meta-analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568157-4000px.png">(PS07-04) Improved uptake and adherence to prevention medication with use of baby tamoxifen in patients at high risk for breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568183-4000px.png">(PS07-06) A novel citrullinated-ENO1 peptide-based vaccine for triple-negative breast cancer prevention</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568237-4000px.png">(PS07-07) The RXR agonist</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568235-4000px.png">(PS07-08) Bazedoxifene plus conjugated estrogen reduces mammary proliferation markers and improves adipocyte size</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568180-4000px.png">(PS07-09) Prenatal BRCA1 epimutations is a major cause of triple-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568255-4000px.png">(PS08-01) Antibody-Drug Conjugates (ADCs) in Breast Cancer: Real World Analysis of Outcomes</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568126-4000px.png">(PS08-02) Efficacy of Sacituzumab-Govitecan (SG) post Trastuzumab-deruxtecan (T-DXd) and vice versa for HER2low advanced or metastatic breast cancer (MBC): a French multicentre retrospective study.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568244-4000px.png">(PS08-03) Sequencing Antibody-Drug Conjugate after Antibody-Drug Conjugate in Metastatic Breast Cancer (A3 study): Multi-Institution Experience and Biomarker Analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568174-4000px.png">(PS08-04) Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568170-4000px.png">(PS08-06) A Phase Ib&#x2F;II Study to Assess the Safety and Efficacy of PM8002 (Anti-PD-L1 x VEGF-A Bispecific Antibody) in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568205-4000px.png">(PS08-07) BL-B01D1</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568224-4000px.png">(PS08-08) Updated efficacy and safety of SKB264 (MK-2870) for previously treated metastatic triple negative breast cancer (mTNBC) in Phase 2 study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568182-4000px.png">(PS08-09) Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568145-4000px.png">(PS09-01) Individual patient data meta-analysis of clinical and translational biomarkers for prediction of pathological complete response (pCR) after de-escalated therapy in HER2+ breast cancer in four trials of the West German Study Group</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568210-4000px.png">(PS09-02) Event-free Survival by Residual Cancer Burden (RCB) and Intratumor HER2 Heterogeneity after Neoadjuvant T-DM1 and Pertuzumab for Early-stage HER2-positive Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568227-4000px.png">(PS09-03) Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568133-4000px.png">(PS09-04) The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: sub-analysis of the APHINITY trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568247-4000px.png">(PS09-06) Tumor infiltrating lymphocytes as a predictor of pathologic complete response to neoadjuvant therapy in HER2 positive breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568230-4000px.png">(PS09-07) SPAG5 as a companion prognostic and predictive test for management of early stage HER2 positive breast cancer (BCs)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568179-4000px.png">(PS09-08) Genomic characterization of endocrine resistance in ER+HER2+ breast cancers in the POETIC Trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568223-4000px.png">(PS09-09) Multiomics profiling and molecular classification refine precision treatment strategies for HER2-positive breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568116-4000px.png">(PS10-01) Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Pathogenic Variants in BRCA1 and BRCA2</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568256-4000px.png">(PS10-02) Association between Germline Mutation Status and Overall Survival among Women with Breast Cancer in Population-based Studies in the United States</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568222-4000px.png">(PS10-03) Impact of Baseline Oestradiol and Testosterone on the Preventive Effect of Anastrozole</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568240-4000px.png">(PS10-04) The Landscape of Somatic Genetic Alterations in Breast Cancers from Carriers of Germline Pathogenic Variants in DNA-repair Genes</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568147-4000px.png">(PS10-06) Contribution of a breast cancer polygenic risk score to mammography artificial intelligence models and breast density for long term breast cancer risk prediction</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568185-4000px.png">(PS10-07) A second-generation polygenic risk score (PRS) based on genetic ancestry improves breast cancer (BC) risk prediction for all ancestries</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568131-4000px.png">(PS10-08) Validation of a clinical image-based AI-risk model for individualized breast cancer screening in a multi-national setting</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568221-4000px.png">(PS10-09) Development of an absolute risk prediction model for premenopausal breast cancer in an international consortium</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568153-4000px.png">(PS11-01) Brain metastases in metastatic breast cancer: prevalence per line of treatment and cumulative incidence in a cohort of 18075 real-world patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568215-4000px.png">(PS11-02) Clinical risk factors of Central Nervous System (CNS)-related death in patients with HER2-positive metastatic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568168-4000px.png">(PS11-03) Comparison of next-generation sequencing (NGS) results from the cerebrospinal fluid</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568188-4000px.png">(PS11-05) Trastuzumab Deruxtecan in patients with HER2[+] or HER2-Low Advanced Breast Cancer and Pathologically Confirmed Leptomeningeal Carcinomatosis: Results from Cohort 5 of the DEBBRAH Study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568238-4000px.png">(PS11-06) Analysis of HER2 expression changes from breast primary to brain metastases including HER2 Low and impact on overall survival</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568213-4000px.png">(PS11-07) High prevalence of HER2-Low and AR expression in breast cancer brain metastases provide novel therapeutic options</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568156-4000px.png">(PS12-02) Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568199-4000px.png">(PS12-03) p53 loss enables HR+ breast cancer escape from CDK4&#x2F;6 inhibitor-induced quiescence via CDK2</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568124-4000px.png">(PS12-04) Inhibition of GPX4 enhances CDK4&#x2F;6 inhibitor activity in breast cancer.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568171-4000px.png">(PS12-06) A phase 2 study of abemaciclib monotherapy for patients with retinoblastoma-positive (Rb+)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568164-4000px.png">(PS12-07) Phase II clinical trial of palbociclib and binimetinib in advanced triple-negative breast cancer (TNBC) with hyperactivation of ERK and&#x2F;or CDK4&#x2F;6</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568154-4000px.png">(PS12-08) MORPHEUS Hormone Receptor-Positive Breast Cancer: interim analysis of a Phase Ib&#x2F;II</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568134-4000px.png">(PS12-09) Capivasertib plus cyclin-dependent kinase 4&#x2F;6 inhibitor and fulvestrant in hormone receptor-positive&#x2F;human epidermal growth factor receptor 2-negative advanced breast cancer: updated Phase 1b analysis from CAPItello-292</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568165-4000px.png">(PS13-01) Worse Prognosis for Breast Cancer in the Second and Third Trimesters and Shortly Postpartum:An Update of the Dutch Pregnancy-Associated Breast Cancer Cohort</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568132-4000px.png">(PS13-02) Clinical Outcome and Patientsâ?Characteristics of Breast Cancer Diagnosed During Pregnancy: A Retrospective Single Institutional Study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568129-4000px.png">(PS13-03) Safety of taxane chemotherapy for the treatment of breast cancer during pregnancy: an international cohort study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568166-4000px.png">(PS13-04) Frequent Intra-Tumoral Hypoxia in Pregnancy-Associated Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568122-4000px.png">(PS13-07) Systemic therapy in geriatric patients with triple negative breast cancer: a National Cancer Database analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568207-4000px.png">(PS13-08) Chemotherapy in geriatric patients with early stage HER2+ breast cancer: A National Cancer Database analysis.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568186-4000px.png">(PS13-09) Molecular and immunological landscape of sex-based differences in breast cancer: a distinct disease in men.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568119-4000px.png">(PS14-01) Immune related adverse events in patients â?5 years vs. &lt; 65 years with breast cancer treated with immunotherapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568242-4000px.png">(PS14-02) Real-world analysis comparing Black and White patients with triple-negative breast cancer receiving therapy per KEYNOTE-522</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568211-4000px.png">(PS14-03) Delayed and post-treatment immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568228-4000px.png">(PS14-05) Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in patients with early triple-negative breast cancer (TNBC)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568187-4000px.png">(PS14-06) Real-World Analysis of Adverse Events in Patients with Triple Negative Breast Cancer Receiving Therapy per KEYNOTE-522</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568136-4000px.png">(PS14-07) Exploring Circulating Leukocyte RNA Expression: Implications for Treatment Outcomes and Immune-Related Adverse Events in Patients with Triple Negative Breast Cancer Enrolled in the GeparNuevo Trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568233-4000px.png">(PS14-08) Safety evaluation from the KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy in patients with previously untreated</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568173-4000px.png">(PS15-01) A first-in-human phase 1 study of SIM0270</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568114-4000px.png">(PS15-02) A Phase â b Study of D-0502 as Monotherapy for Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer: Results from the Dose-Expansion Stage</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568158-4000px.png">(PS15-03) Vepdegestrant</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568123-4000px.png">(PS15-04) A Phase 1b&#x2F;2 study of palazestrant (OP-1250)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568130-4000px.png">(PS15-06) Results of the window-of-opportunity PIONEER trial evaluating addition of the progesterone receptor (PR) agonist megestrol to letrozole for early stage estrogen receptor (ER) positive breast cancer: exploiting ER-PR interaction</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568220-4000px.png">(PS15-07) Proxalutamide plus Endocrine Therapies in Women with HR+&#x2F;HER2-&#x2F;AR+ Metastatic Breast Cancer: A Phase Ic Study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568231-4000px.png">(PS15-08) Final Overall Survival (OS) analysis of the SAKK 21&#x2F;12 trial. CR1447 in HR+&#x2F;HER2- metastatic breast cancer and androgen receptor positive triple negative breast cancer.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568115-4000px.png">(PS15-09) Imlunestrant monotherapy and in combination with abemaciclib</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571173-4000px.png">(PS16-01) Comparison of an Atezolizumab monotherapy window followed by Atezolizumab and chemotherapy vs. Atezolizumab and chemotherapy alone in triple negative breast cancer (TNBC) â?final analysis of the neoadjuvant neoMono trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571175-4000px.png">(PS16-02) Efficacy and safety of first-line atezolizumab + bevacizumab + paclitaxel in patients with advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568236-4000px.png">(PS16-03) Intratumoral dosing of INT230-6 in Early-Stage Breast Cancer Patients Induces Tumor Cell Necrosis and Immunomodulatory Effects: A Phase II Randomized Window-Of-Opportunity Study â?the INVINCIBLE Trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568143-4000px.png">(PS16-04) Denosumab as an enhancer of the immune infiltrate in hormone receptor-positive early breast cancer. Subgroup analysis from the D-Biomark window-of-opportunity clinical trial (NCT03691311)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568200-4000px.png">(PS16-06) Tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: A single-center real-world study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568163-4000px.png">(PS16-07) Tumor infiltrating lymphocyte stratification refines AJCC TNM staging based outcomes of early-stage triple negative breast cancer treated with neoadjuvant anthracycline-free</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568245-4000px.png">(PS16-08) Histologic Pattern and Outcomes in High-Grade Metaplastic Breast Cancer Compared to Triple-Negative Ductal Breast Cancer Counterparts: A Single Institution Retrospective Study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568250-4000px.png">(PS16-09) Analysis of the Radiosensitivity Index&#x2F;Genomic-Adjusted Radiation Dose (RSI-GARD) in paired pre- and post-treatment TNBC samples: implications for biomarker-guided radiotherapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568203-4000px.png">(PS16-10) SPATIAL IMMUNE CELL DISTRIBUTION CAN REFINE PROGNOSIS IN EARLY-STAGE ER+&#x2F;HER2-&#x2F;LN- BREAST CANCER</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568137-4000px.png">(PS17-01) Key drivers of therapeutic response and resistance to giredestrant from GO39932: a Phase Ia&#x2F;b study in patients with estrogen receptor-positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568140-4000px.png">(PS17-02) Elacestrant vs standard-of-care in ER+&#x2F;HER2- advanced or metastatic breast cancer (mBC) with ESR1 mutation: key biomarkers and clinical subgroup analyses from the phase 3 EMERALD trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568146-4000px.png">(PS17-03) Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR positive&#x2F;HER2-negative advanced breast cancer: exploratory analysis of PFS by AKT pathway gene from the Phase 3 CAPItello-291 trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568149-4000px.png">(PS17-04) Clinical and Genomic Features of ER-Positive&#x2F;HER2-negative Metastatic Breast Cancer in AURORA Molecular Screening Initiative (BIG 14-01): Mechanisms of Endocrine Therapy Resistance and Implications for Adjuvant Approaches</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568148-4000px.png">(PS17-06) A phase I trial of the PI3K inhibitor (PI3Ki) copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor-positive (ER+)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568162-4000px.png">(PS17-07) Interim analysis of giredestrant + inavolisib in MORPHEUS Breast Cancer: a Phase Ib&#x2F;II study of giredestrant treatment combinations in estrogen receptor-positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568138-4000px.png">(PS17-08) A Phase Ib Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients with Locally Advanced or Metastatic HR+&#x2F;HER2- Breast Cancer Who Failed Standard of Care Therapies</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568191-4000px.png">(PS17-09) An FGFR1&#x2F;2 degrader overcomes antiestrogen resistance in ER+&#x2F;FGFR1-amplified breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568139-4000px.png">(PS18-01) Stage Advancement and The Rate of Growth Associated with Preoperative Delay in Patients Having Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568141-4000px.png">(PS18-02) Prevalence of Refusal of Recommended Cancer Treatments and Survival Differences in Breast Cancer Patients: Analysis of the National Cancer Database</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568196-4000px.png">(PS18-03) The Association between Food Deserts</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568150-4000px.png">(PS18-04) Racial disparities in breast cancer and effect of obesity: MammaPrint</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568248-4000px.png">(PS18-08) Bridging Disparities in Survivorship Care: Leveraging Telehealth for Diverse Patients in Safety Net Hospital</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568232-4000px.png">(PS18-09) The DARC side of Breast Cancer - DARC</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2568127-4000px.png">(PS18-10) Tumor-Infiltrating Lymphocytes and Breast Cancer Mortality in Racially and Ethnically Diverse Participants of the Northern California Breast Cancer Family Registry</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566158-4000px.png">(PO1-01-01) ECOG-ACRIN EA1211: Interim FDG-PET&#x2F;CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT Trial)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566475-4000px.png">(PO1-01-02) Final analysis of neoadjuvant chemotherapy with pegylated liposomal doxorubicin&#x2F; cyclophosphamide followed by taxanes with full-course trastuzumab&#x2F;pertuzumab for HER2-positive breast cancer: a single-arm</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566300-4000px.png">(PO1-01-03) Pathological response according to early metabolic remission in an interim FDG-PET scan and to tumor infiltrating lymphocytes - A secondary analysis of the phase II trial ABCSG 52 &#x2F; ATHENE investigating atezolizumab in early HER2+ BC</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566315-4000px.png">(PO1-01-04) The optimal neoadjuvant treatment regimen for HR+&#x2F;HER2+ breast cancer: a network meta-analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566352-4000px.png">(PO1-01-05) Spatial PK&#x2F;PD Model with HER2 Expression for Predicting Individual Tumor Response to T-DM1</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566364-4000px.png">(PO1-01-06) Patterns in use and tolerance of adjuvant neratinib in patients with hormone receptor (HR)-positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566088-4000px.png">(PO1-01-07) Cryoablation and endocrine therapy for clinical stage I&#x2F;II</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566099-4000px.png">(PO1-01-08) The impact of drug-drug interactions between palbociclib and proton pump inhibitors on clinical outcomes of patients with hormone receptor positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566106-4000px.png">(PO1-01-09) Neoadjuvant endocrine therapy and avelumab with or without palbociclib in stage II&#x2F;III endocrine receptor-positive breast cancer: the ImmunoADAPT trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566136-4000px.png">(PO1-01-10) Comparison of the cost-effectiveness of multigene assays for HR+&#x2F;HER2- node-negative early-stage breast cancer in the US</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566142-4000px.png">(PO1-01-11) Development and Validation of a Breast Cancer Recurrence Model Demonstrates Accurate Identification of Patients with Favorable Long-Term Outcomes</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566166-4000px.png">(PO1-01-12) A retrospective cohort study on the effect of adding adjuvant ovarian function suppression to endocrine therapy in premenopausal women with T1-T2 tumor hormone-positive breast cancer on survival and disease recurrence.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566179-4000px.png">(PO1-01-13) Clinical characterization</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566214-4000px.png">(PO1-02-01) T Cell Receptor Sequencing to Monitor Pelareorep-Induced Expansion of Tumor Infiltrating Lymphocytes</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566249-4000px.png">(PO1-02-02) Update of RSClin with extended TAILORx follow-up and development and validation of a new tool for risk of late distant recurrence</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566295-4000px.png">(PO1-02-03) Correlative analysis of Breast Cancer Index with CTS5 for prediction of extended endocrine benefit in the BCI Registry study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566299-4000px.png">(PO1-02-04) The efficacy of endocrine therapy during the waiting period for surgery for hormone receptor-positive breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566323-4000px.png">(PO1-02-05) An exploratory comparison of MINDACT and TAILORx genomic risk proportions and outcomes in patients with HR+&#x2F;HER2-</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566137-4000px.png">(PO1-02-07) HER2 Low Non-Metastatic Breast Cancer in Qatar: A Nationwide Retrospective Cohort Study to Evaluate the Response to Neoadjuvant Chemotherapy: A Real-World Analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566145-4000px.png">(PO1-02-08) Comprehensive Molecular Profiling of Breast Cancer: A real-time PCR assay for identifying ESR1</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566178-4000px.png">(PO1-02-09) Efficacy of breast conserving treatment of minimal residual tumors after neoadjuvant therapy for breast cancer.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566270-4000px.png">(PO1-02-11) Characterization of MammaPrint UltraLow Risk tumors in more than 1400 patients from the real-world evidence FLEX study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566304-4000px.png">(PO1-02-12) Nutritional guidance effect on anthropometric and inflammatory parameters in young women with breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566319-4000px.png">(PO1-02-13) Germline mutation status of BRCA1&#x2F;2 and other breast cancer predisposition genes as predictive and prognostic biomarker: Results of the GeparX study (GeparX-BRCA)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566344-4000px.png">(PO1-02-14) Breast cancer in older women - long-term prognosis by age and subtype in a large population-based cohort</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566356-4000px.png">(PO1-03-01) Barriers</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566377-4000px.png">(PO1-03-02) Impact of Body Mass Index (BMI) on the efficacy of different adjuvant chemotherapy schedules in patients with breast cancer: analysis from the randomized phase III GIM2 trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566445-4000px.png">(PO1-03-03) STEEP criteria v2.0 validation: A multi-trial analysis using GEICAM and TRIO adjuvant trials to evaluate surrogate endpoints for overall survival</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566087-4000px.png">(PO1-03-05) Tolerance of adjuvant radiotherapy combined with pembrolizumab for triple negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566154-4000px.png">(PO1-03-06) Older patients with Early Stage Triple Negative Breast Cancer: The Memorial Sloan Kettering Cancer Center experience.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566192-4000px.png">(PO1-03-07) Revisiting the potential of pathological complete response as a surrogate for long-term survival outcomes in triple-negative breast cancer at the trial-level</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566334-4000px.png">(PO1-03-08) Association of patient-reported triple-negative breast cancer (TNBC) knowledge with clinical trial participation</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566415-4000px.png">(PO1-03-09) Transcriptomic profiling of ER-negative and ER-low</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566438-4000px.png">(PO1-03-10) Differential microbial metabolic pathways associated with resistance to neoadjuvant immunotherapy in locally advanced triple negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566539-4000px.png">(PO1-03-11) Camrelizumab in Combination with Nab-Paclitaxel and Carboplatin versus Nab-Paclitaxel and Carboplatin as Neoadjuvant Therapy for Triple Negative Breast Cancer: A Multicenter</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566079-4000px.png">(PO1-04-01) Phase 1 dose escalation study of ARX788</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566162-4000px.png">(PO1-04-02) ACE-Breast-03: A phase 2 study of ARX788</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566161-4000px.png">(PO1-04-03) Phase I&#x2F;II Trial of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566151-4000px.png">(PO1-04-04) Inetetamab combined with pyrotinib and oral vinorelbine for patients with HER2-positive metastatic breast cancer: a single-arm phase 2 trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566211-4000px.png">(PO1-04-05) Effectiveness and safety of inetetamab + pyrotinib + vinorelbine in â¥second-line treatment of HER2-positive metastatic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566267-4000px.png">(PO1-04-06) Exposure-response analyses of sacituzumab govitecan efficacy and safety in patients with metastatic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566365-4000px.png">(PO1-04-07) Disitamab vedotin</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566119-4000px.png">(PO1-04-10) Body Mass Index and Treatment Efficacy in advanced Luminal Breast Cancer: Insights from the GEICAM&#x2F;2013-02 (PEARL) trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566157-4000px.png">(PO1-04-12) Palbociclib versus ribociclib in first-line treatment of patients with hormone-receptor positive HER2 negative advanced breast cancer â?real world outcome data from the German registry platform OPAL</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566164-4000px.png">(PO1-04-13) CARDIAC-STAR: Prevalence of Cardiovascular Comorbidities in Hormone Receptor Positive Human Epidermal Growth Factor Negative metaStatic breasT cAnceR</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566188-4000px.png">(PO1-04-14) PLK1 Inhibitor Onvansertib Extends the Response and Overcomes Resistance to Paclitaxel in Palbociclib-resistant HR+ Breast Cancer Patient-derived Xenografts.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566193-4000px.png">(PO1-05-01) Cyclin-dependent Kinase 4&#x2F;6 Inhibitors Combined with Radiotherapy in the Management of Brain Metastases in HR-positive&#x2F;HER2-negative Breast Cancer Patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566208-4000px.png">(PO1-05-02) CDK4&#x2F;6 inhibitors in advanced breast cancer (aBC). Preliminary results of the CDK4&#x2F;6i choice and sequence of treatments in a series of 174 patients. GOIRC-04-2019 retro&#x2F;prospective observational study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566268-4000px.png">(PO1-05-04) CDK4&#x2F;6 inhibitor-induced Interstitial Lung Disease (ILD) - A Case Series</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566277-4000px.png">(PO1-05-05) Overall survival (OS) and subsequent therapy patterns in Japanese patients with HR+&#x2F;HER2â?advanced breast cancer (ABC) treated with palbociclib (PAL) plus letrozole (LET) in first-line setting (1L)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566278-4000px.png">(PO1-05-06) Health-related QOL and physical activity collected via wearable device in patients with HR+&#x2F;HER2â?advanced breast cancer in Japan treated with palbociclib+endocrine therapy (ET) or ET alone: 6-month longitudinal study (JBCRG-26)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566281-4000px.png">(PO1-05-07) Circulating tumor DNA dynamics in acelERA Breast Cancer: a Phase II study of giredestrant for estrogen receptor-positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566283-4000px.png">(PO1-05-08) Enhanced ER+ tumor growth inhibition of fulvestrant from effective oral delivery yielding elevated plasma concentrations</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566285-4000px.png">(PO1-05-09) ASCENT-07: A phase 3</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566127-4000px.png">(PO1-05-10) Clinical effectiveness of CDK4&#x2F;6 inhibitors in HER2-low metastatic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566141-4000px.png">(PO1-05-11) Efficacy of metformin as adjunctive therapy in patients with de novo metastatic breast cancer: a retrospective cohort study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566203-4000px.png">(PO1-05-12) Pooled clinical trial data analyses comparing the biology of HER2-low vs HER2-0 breast cancer in patients with metastatic breast cancer following treatment with standard single agent chemotherapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566221-4000px.png">(PO1-05-13) Drop-out rates from line to line of treatment in metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566241-4000px.png">(PO1-05-14) Outcomes of first-line chemotherapy for visceral crisis in metastatic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566257-4000px.png">(PO1-06-01) Clinical Efficacy of Tumor Organoid-Guided Cancer Therapy for Locally Advanced Unresectable or Metastatic Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566258-4000px.png">(PO1-06-02) Solti-1716 TATEN phase II trial: Targeting non-Luminal disease by PAM50 with pembrolizumab and paclitaxel in Hormone Receptor-positive&#x2F;HER2-negative advanced breast cancer (ABC)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566259-4000px.png">(PO1-06-03) Efficacy of First-line Treatments for Hormone Receptor-positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566265-4000px.png">(PO1-06-04) Immune checkpoint inhibitors for triple-negative inflammatory breast cancer (INCORPORATE): an international multicenter retrospective analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566309-4000px.png">(PO1-06-05) Heterogeneity and prognostic characteristics of HER2-low breast cancer: A retrospective analysis of patients with HER2-negative metastatic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566339-4000px.png">(PO1-06-06) Underestimation of metastatic spread in patients with lobular breast cancer: results from the post-mortem tissue donation program UPTIDER</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566107-4000px.png">(PO1-06-07) EMSY enhances cancer stem cell self-renewal and tumorigenesis by reshaping methionine metabolism in triple-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566216-4000px.png">(PO1-06-08) Treatment utilization by race and insurance type among triple negative breast cancer patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566232-4000px.png">(PO1-06-09) Phase 2 Trial with Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1&#x2F;2 Positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566266-4000px.png">(PO1-06-10) Overall survival results from EVER-132-001</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566284-4000px.png">(PO1-06-11) Exosomal HMGB1 induce PD-L1+-tumor associated macrophages through glycometabolic reprogramming to promote lung-tropic metastasis of triple negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566314-4000px.png">(PO1-06-12) Phase II study of sitravatinib plus tislelizumab with or without nab-paclitaxel in patients with locally recurrent or metastatic triple negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566331-4000px.png">(PO1-06-13) Plasma Exosomes in Obesity-driven Diabetes Exacerbate Progression of Triple Negative Breast Cancer: Insights from Animal Models</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566376-4000px.png">(PO1-06-14) Preliminary results of a phase I dose escalation study of eribulin in combination with copanlisib in patients with metastatic triple negative breast cancer (TNBC)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566090-4000px.png">(PO1-07-01) Artificial intelligence-based prediction of Oncotype DX Score from whole slide images using human-interpretable features and breast biomarkers</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566113-4000px.png">(PO1-07-02) Sensitive tumor detection</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566253-4000px.png">(PO1-07-04) Multiomics analysis reveals the landscape of PD-L1 expression in triple-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566305-4000px.png">(PO1-07-05) Preliminary Evaluation in Breast Cancer of PointCheck: a Noninvasive AI-Based Neutropenia Monitoring Device</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566108-4000px.png">(PO1-07-06) Sonographic assessment of breast implants using strain elastography and shear wave elastography in an animal model</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566255-4000px.png">(PO1-07-08) Value of high resolution full field optical coherence tomography and dynamic cell imaging (D-FFOCT) for one-stop rapid diagnosis breast clinic</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566261-4000px.png">(PO1-07-09) Benefit of Adherence to Annual Mammography Screening: Results from 8</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566293-4000px.png">(PO1-07-10) Blood Based Early Cancer Detection Assay</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566301-4000px.png">(PO1-07-11) Radiogenomic-based imaging intratumor heterogeneity model predicts breast cancer prognosis and unveils therapeutic targets</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566322-4000px.png">(PO1-07-12) Inverse modeling with surface temperature accurately detects the presence of breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566082-4000px.png">(PO1-08-01) Identifying a founder BRCA1 variant in the Qatari population With unique genotype â?phenotype correlations</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566098-4000px.png">(PO1-08-02) Population-based screening of Uruguayan Ashkenazi Jews for recurrent BRCA1 and BRCA2 pathogenic sequence variants</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566100-4000px.png">(PO1-08-03) Using Telehealth to Establish a High Risk Cancer Prevention Clinic over a large Geographic Area</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566105-4000px.png">(PO1-08-04) Universal Germline Genetic Testing for Breast Cancer: Implementation in a Rural Practice and Impact on Shared Decision Making</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566124-4000px.png">(PO1-08-05) Using the CTS5 Score to Predict Late Recurrence in Male and Female Estrogen Receptor-Positive Breast Cancer Patients: a SEER database analysis of 65</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566156-4000px.png">(PO1-08-06) Clinical-molecular correlation in breast cancer with pathogenic variants in CHEK2. Is there a relationship with HER2+ breast cancer?</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566183-4000px.png">(PO1-08-07) Utilization Management: The Impact of Laboratory Genetic Counseling Oversight on BRCA1 and BRCA2 Targeted Analysis Orders</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566219-4000px.png">(PO1-08-08) Hereditary cancer genetic testing in Puerto Rican females</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566237-4000px.png">(PO1-08-09) Drynaria fortunie</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566251-4000px.png">(PO1-08-10) Impact of Oncologist-Led Genetic Counseling and Testing on Prophylactic Mastectomy Rates Among Multi-Ethnic Women with Operable Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566279-4000px.png">(PO1-08-11) The survival rate of hereditary breast cancer in young women of Kazakh population</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2576711-4000px.png">(PO1-08-12) Genomic Characterization of the Carolina Breast Cancer Study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566311-4000px.png">(PO1-09-01) Patient Advocates</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566316-4000px.png">(PO1-09-02) Universal genetic testing for women with newly diagnosed breast cancer identified many mutations</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566413-4000px.png">(PO1-09-03) Clinical Impact of Multigene Panel Testing in Patients with a Personal or Family History of Breast or Ovarian Cancer Previously Negative for BRCA1&#x2F;2 Genes</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566104-4000px.png">(PO1-09-05) Reversing Rural Disparity Through Increased Access to Breast Care Using Model of Academic-Community Collaboration</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566147-4000px.png">(PO1-09-06) Patient Barriers to Genetic Counseling</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2576705-4000px.png">(PO1-09-07) Outpatient mastectomy is a safe surgical option for patients treated in a rural Appalachian tertiary facility</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566206-4000px.png">(PO1-09-08) Mammography adherence modifies the relationship between multilevel social deprivation and tumor characteristics in the Carolina Breast Cancer Study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2576702-4000px.png">(PO1-09-09) The journey of HR positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566235-4000px.png">(PO1-09-10) County-level Social Vulnerability and Survival among Women with Inflammatory Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566273-4000px.png">(PO1-09-11) Racial Differences in Pathologic Complete Response Rate and Overall Survival Following Neoadjuvant Chemotherapy for Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566839-4000px.png">(PO1-09-12) Cancer health disparities among patients with early-stage estrogen receptor-positive (ER+) breast cancer treated in public or private practices in Brazil</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566325-4000px.png">(PO1-10-01) Racial&#x2F;Ethnic Disparities in Rates of Pathological Complete Response and Survival in Patients with Inflammatory Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566374-4000px.png">(PO1-10-03) Prevalence of and Factors Associated with Food Insecurity and Other Adverse Social Determinants of Health Among Breast Oncology Patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566390-4000px.png">(PO1-10-04) Racial and Ethnic Disparities in Anthracycline and HER2-targeted Cardiotoxicity in Patients With Breast Cancer Using Global Longitudinal Strain Imaging Techniques</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566202-4000px.png">(PO1-10-06) Understanding clinical meaningfulness in metastatic breast cancer treatment decision-making: experiences and perspectives of patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566571-4000px.png">(PO1-10-07) A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients with Metastatic Breast Cancer: Primary Results of a Prospective Intervention Trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566290-4000px.png">(PO1-10-08) Building awareness of triple negative breast cancer: Results from the Canadian Breast Cancer Network national survey</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566298-4000px.png">(PO1-10-09) The Performance Of Mobile Units Versus Hospital Units In National Breast Cancer Screening Program In Taiwan</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566326-4000px.png">(PO1-10-10) Leveraging technology to optimize symptom management and patient empowerment in routine breast cancer care: implementation of a remote patient monitoring (RPM) pathway across 24 hospitals in Europe</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566459-4000px.png">(PO1-10-11) Illuminating Breast Cancer Clinical Trials: Unpublication Rates</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566458-4000px.png">(PO1-10-12) Advancing Gender Equity: A Closer Look at Women’s Representation in Leading Breast Cancer Clinical Trials</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566357-4000px.png">(PO1-11-01) Effectiveness of Susan G. Komenâs national telehealth patient navigation model in reaching underserved populations and reducing cancer-related distress</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566464-4000px.png">(PO1-11-02) Reporting of Post-protocol Therapies in Metastatic Breast Cancer Registration Clinical Trials: A Systematic Review</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566094-4000px.png">(PO1-11-03) Women with Metastatic Disease: Modeling a Clear and Well-Defined Announcement Pathway</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566095-4000px.png">(PO1-11-04) Breast cancer patient perspectives on the need for psychotherapy and the roll of physician referrals for improved quality of life during and post treatment</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566121-4000px.png">(PO1-11-05) Diet quality and cardiovascular disease risk among breast cancer survivors in the Pathways Study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566159-4000px.png">(PO1-11-06) Evaluating Symptom Clusters in Patients with Breast Cancer Experiencing Aromatase Inhibitor-Associated Musculoskeletal Symptoms</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566223-4000px.png">(PO1-11-07) Do factors other than type of surgery performed for breast cancer affect quality of life and sexual functioning in breast cancer survivors? An observational study from Northern India.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566225-4000px.png">(PO1-11-08) Late effects of breast cancer treatment among long term breast cancer survivors in the Carolina Breast Cancer Study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566231-4000px.png">(PO1-11-09) Body composition correlates with BMI and menopausal status in patients with breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566250-4000px.png">(PO1-11-10) Use of a standardized tool for the evaluation and treatment of cancer related cognitive impairment (chemo-brain) among breast cancer patients.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566260-4000px.png">(PO1-11-11) A Novel Body Composition Risk Score (B-Score) and Overall Survival among Patients with Early-Stage Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566337-4000px.png">(PO1-11-12) Factors associated with treatment failure for chemotherapy-induced nausea and vomiting (CINV) among breast cancer patients receiving adjuvant chemotherapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566370-4000px.png">(PO1-12-01) ‘Not even my husband knows that I have this [breast cancer]’: Survivorsâ?Experiences in Accessing</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566379-4000px.png">(PO1-12-02) Impact of Discontinuation of Denosumab on Bone Health in Breast Cancer Patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566391-4000px.png">(PO1-12-03) Quality of Life in Patients Diagnosed and Treated for Breast Cancer in Uruguay</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566443-4000px.png">(PO1-12-04) Exploring Factors Associated with Sexual Well-being and Breast Satisfaction Among Women with Early-stage Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566097-4000px.png">(PO1-12-06) Is it appropriate to select patients for primary prophylactic use of pegfilgrastim based on the risk of febrile neutropenia?</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566120-4000px.png">(PO1-12-07) Denosumab vs. Pamidronate in the Management of Osteolytic Bone Metastases Secondary to Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566139-4000px.png">(PO1-12-09) Doublet or triplet antiemetic prophylaxis for trastuzumab deruxtecan-induced nausea and vomiting: An open-label</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566180-4000px.png">(PO1-12-10) Zoledronic acid to prevent rebound fractures after stopping adjuvant denosumab: a randomized controlled sub-study of the ABCSG-18 trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566213-4000px.png">(PO1-12-11) How do chemotherapy and age affect physical performance in breast cancer patients over 12 months of treatment? Results from the UPBEAT Study (UPBEAT WF-97415)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566296-4000px.png">(PO1-13-01) Safety profiles of Chinese breast cancer patients who received abemaciclib in MONARCH plus and monarchE study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566102-4000px.png">(PO1-13-02) Circulating tumor DNA mutation landscape in HR+&#x2F;HER2â?patients with mBC treated with cyclin-dependent kinase 4&#x2F;6 inhibitors in the SCRUM-Japan MONSTAR-SCREEN study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566130-4000px.png">(PO1-13-03) Tumour infiltrating double negative (CD20+CD27- IgD-) B cells in high-risk early breast cancers. Friend or Foe??</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566131-4000px.png">(PO1-13-04) Distinct immune signatures discriminate between patients defined as exceptional survivors of metastatic breast cancer compared to those with rapidly progressing treatment resistant breast cancers.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566132-4000px.png">(PO1-13-05) Genomic characteristics and its therapeutic implications in breast cancer patients with detectable molecular residual disease</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566133-4000px.png">(PO1-13-06) Androgen Receptor Isoform V7 (AR-V7): A Promising Biomarker for Prognosticating Breast Cancer Aggressiveness</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566163-4000px.png">(PO1-13-07) LIV-1 and Trop2 expression using Immunohistochemistry as prognostic markers in early breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566207-4000px.png">(PO1-13-12) Mechanistic Analysis and Potential Therapeutic Implications in Breast Cancer with Fibrotic Focus</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566210-4000px.png">(PO1-14-01) Clonal Architecture of circulating tumor DNA predicts Early Progression on Tamoxifen With or Without Palbociclib in Hormone Receptor-Positive Advanced Breast Cancer: NCCH1607&#x2F;PATHWAY trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566217-4000px.png">(PO1-14-02) Real world application of a 21-gene recurrence score in a Swiss single center breast cancer population. A comparative analysis of treatment administration before and after TAILORx</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566222-4000px.png">(PO1-14-03) Discovery of proliferation essential gene signature and ACTL6A as potential biomarker for predicting prognosis and neoadjuvant therapy response in triple-positive breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566238-4000px.png">(PO1-14-04) A multivariate biomarker to guide antibody-drug conjugate selection and provide insight on response differences across breast cancer subtypes</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566239-4000px.png">(PO1-14-05) A comparison of chemotherapy recommendations by NPI</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566271-4000px.png">(PO1-14-08) Real-world clinical genomics study of HR+&#x2F;HER2- metastatic breast cancers treated by CDK4&#x2F;6i plus endocrine therapies revealed a drug resistant tumor segment characterized by ER independence</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566282-4000px.png">(PO1-14-09) Age-related remodeling of the systemic and breast microenvironment promotes a tumor-permissive locale for ER+ breast cancer in older women</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566324-4000px.png">(PO1-14-10) Comprehensive clinicogenomic characterization of inflammatory breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566329-4000px.png">(PO1-14-11) Different molecular processes are associated with recurrence in the clinical high- genomic low risk (cH&#x2F;gL) and clinical low- genomic high risk (cL&#x2F;gH) groups of the MINDACT clinical trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566335-4000px.png">(PO1-14-12) Quantitative Biomarkers and 21-Gene Assay Results Predict Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566336-4000px.png">(PO1-15-01) Digital pathology models reveal case-specific characteristics of the tumor microenvironment</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566346-4000px.png">(PO1-15-03) Spatially resolved analysis of tumor microenvironment in invasive lobular carcinoma</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566358-4000px.png">(PO1-15-04) Young Black Women With Triple-Negative Breast Cancer Molecular Subtypes: Population-Specific Patterns and Batch Effect Considerations</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566380-4000px.png">(PO1-15-05) Gene expression signature as a predictor of pathological complete response to neoadjuvant docetaxel</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567012-4000px.png">(PO1-15-06) Serum thymidine kinase activity as a âreal-timeâ?clinical biomarker of tumor response to CDK4&#x2F;6 inhibition in hormone receptor positive (HR+)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566402-4000px.png">(PO1-15-10) Lower pre-treatment B-cell gene expression signatures correspond with improved overall survival with palbociclib + endocrine therapy in HR+&#x2F;HER2- metastatic breast cancer: a biomarker analysis from the GEICAM&#x2F;2013-02 PEARL trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566404-4000px.png">(PO1-15-11) Molecular and clinical disparities in breast cancer among East Asian populations</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566405-4000px.png">(PO1-15-12) Circulating tumor DNA (ctDNA) for prediction of pathologic complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched early breast cancer: WSG-Keyriched-1 trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566409-4000px.png">(PO1-16-01) Clinicopathological and global transcriptional complexity of estrogen receptor low positive breast cancers in a contemporary Swedish prospective population-based cohort.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566417-4000px.png">(PO1-16-02) Correlation of Circulating Tumor Cells (CTC) with Clinical Characteristics</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566421-4000px.png">(PO1-16-03) GDP-mannose enhances the efficacy of PARP inhibitors and immunotherapy in triple-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566432-4000px.png">(PO1-16-04) Targeting PKMYT1 Kinase as a Therapeutic Strategy for Treatment of Triple Negative Breast Cancer with Low Molecular Weight Cyclin E (LMW-E) Expression</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566454-4000px.png">(PO1-16-05) Matched multi-analyte and multi-omic liquid biopsy of cell-free DNA</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566077-4000px.png">(PO1-16-06) LuciA-15 - A real-world prospective study of PARP inhibitors for the treatment of Latin American patients with HER-2 negative metastatic breast cancer with mutation of BRCA1&#x2F;2 genes or in the Homologous Recombination Repair genes.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566086-4000px.png">(PO1-16-07) Patient Characteristics and Treatment Sequencing Among HER2-low Metastatic Breast Cancer Patients with Rapid vs. Delayed Progression on First-line Endocrine Therapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566423-4000px.png">(PO1-16-08) Real-World Outcomes of Patients Receiving First-line Palbociclib Plus Endocrine Therapy in Spain: Subgroup Analysis Based on Tumor Grade</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566140-4000px.png">(PO1-16-09) Does T1c-2N0-1M0 triple negative breast cancer derive a benefit from neoadjuvant chemotherapy?</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566173-4000px.png">(PO1-16-10) BRCA mutated Male Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566177-4000px.png">(PO1-16-11) Real-world features and outcomes of young advanced breast cancer (ABC) patients (pts) from RegistEM (GEICAM&#x2F;2014-03) study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566182-4000px.png">(PO1-16-12) The McPeak-Sirois Group Breast Metastases Registry</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566205-4000px.png">(PO1-17-01) Surgical Margins and prognosis of borderline and malignant phyllodes tumors of breast</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566246-4000px.png">(PO1-17-02) Real-world outcomes of systemic therapy for advanced triple-negative breast cancer: a tertiary centre experience</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566274-4000px.png">(PO1-17-03) Real-world evidence of Trastuzumab biosimilars in HER2-positive breast cancer: Evaluating utilization</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566275-4000px.png">(PO1-17-04) Influence of regulatory agency approval of trastuzumab-deruxtecan on the diagnosis of HER2-low status at a reference cancer center in Brazil</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566292-4000px.png">(PO1-17-05) Real-world effectiveness of palbociclib plus aromatase inhibitors (AI) in metastatic breast cancer patients with cardiovascular diseases</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566310-4000px.png">(PO1-17-06) Driving diversity in research participation with ShareForCuresâ? a patient-centered</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566328-4000px.png">(PO1-17-07) Invasive disease-free survival as a surrogate for overall survival in patients with hormone receptorâpositive&#x2F;human epidermal growth factor receptor 2ânegative early breast cancer: a real-world analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566345-4000px.png">(PO1-17-08) Post-approval treatment patterns and tolerability of neratinib in HER2+ early-stage breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566362-4000px.png">(PO1-17-09) Real-world clinical outcomes in US patients with brain metastases secondary to HR+&#x2F;HER2- metastatic breast cancer treated with abemaciclib</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566366-4000px.png">(PO1-17-10) Impact of COVID19 on neoadjuvant endocrine therapy use in breast cancer: A National Cancer Database analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566368-4000px.png">(PO1-17-11) Trends in post-mastectomy reconstruction by age in Korea and among Asian-Americans</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566397-4000px.png">(PO1-17-12) The impact of treatment sequence of CDK4&#x2F;6 inhibitor therapy on Metastatic Breast Cancer treatment outcomes in Real-World practice in U.S.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566407-4000px.png">(PO1-18-01) Patient Preferences for HR+&#x2F;HER2- Metastatic Breast Cancer Treatments in Italy: A Qualitative Assessment</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2576708-4000px.png">(PO1-18-02) Histologic grade is a better predictor of specific survival than Ki67 in localized ER+&#x2F;HER2- breast cancer: a real-world study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566114-4000px.png">(PO1-18-03) Chemokine-modulating regimen (rintatolimod</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566169-4000px.png">(PO1-18-04) Neoadjuvant pembrolizumab + decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2- breast cancer (NCT02957968)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566212-4000px.png">(PO1-18-05) Combination treatment with CDK2 inhibitor (BLU-222) and either palbociclib or ribociclib is synergistic in pre-clinical models of CDK4&#x2F;6 inhibitor-resistant breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566224-4000px.png">(PO1-18-06) Phase 1&#x2F;2a Open-label Clinical Trial of BI-1607</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566272-4000px.png">(PO1-18-07) Phase I trial of combination pembrolizumab and ruxolitinib in metastatic triple negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566378-4000px.png">(PO1-18-10) ANNE: A phase II single-arm clinical trial to assess the feasibility and efficacy of neoadjuvant anastrozole in patients with luminal breast cancer and low proliferative index in TNM stages II and III.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566084-4000px.png">(PO1-18-11) Imaging of tumour microvasculature using high-resolution contrast enhanced ultrasound together with markers of proliferation&#x2F; angiogenesis&#x2F; vascular mimicry to characterise response to NACT in TNBC</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566092-4000px.png">(PO1-18-12) Trial in progress: Open-label</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566230-4000px.png">(PO1-19-01) NRG-BR008: A Phase III Randomized Trial of Radiotherapy Optimization for Low-risk HER2-positive Breast Cancer (HERO)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566117-4000px.png">(PO1-19-02) A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566144-4000px.png">(PO1-19-03) The T-REX trial: a randomized international non-inferiority trial on Tailored Regional EXternal beam radiotherapy in clinically node-negative breast cancer patients with 1-2 sentinel node macrometastases</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566444-4000px.png">(PO1-19-04) Dalpiciclib and tucidinostat in patients with HR+&#x2F;HER2- advanced breast cancer and resistance to CDK4&#x2F;6 inhibitors: A phase Ib trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566155-4000px.png">(PO1-19-05) COGNITION &#x2F; -GUIDE â?Implementation of Precision Oncology in Early High-Risk Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566167-4000px.png">(PO1-19-06) Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: the randomized Neo-ACT trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566172-4000px.png">(PO1-19-07) A Phase I Study Accessing Immunotherapy Combination of Balstilimab and Ivermectin in Patients with Metastatic Triple Negative Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566185-4000px.png">(PO1-19-08) Phase I trial of pegylated liposomal doxorubicin chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566191-4000px.png">(PO1-19-09) Integrating gene signatures to guide HR+ MBC therapy in a diverse cohort (INSIGHT)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566218-4000px.png">(PO1-19-10) Durvalumab + datopotamab deruxtecan in patients with PD-L1 positive advanced&#x2F;metastatic triple-negative breast cancer: Arm 8 of the phase 1b&#x2F;2</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566220-4000px.png">(PO1-19-11) Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ Metastatic Breast Cancer (HER2CLIMB-05</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566227-4000px.png">(PO1-19-12) VERITAC-2: a phase 3 study of vepdegestrant</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566115-4000px.png">(PO1-20-01) A Prospective Single-Arm Pilot Interventional Trial to Assess Individual Breast Cancer Risk Prior to Gender-Affirming Chest Masculinization Surgery</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566229-4000px.png">(PO1-20-02) MiRaDor: A proof-of-concept study of treatment efficacy by monitoring Minimal Residual Disease (MRD) using circulating tumor DNA (ctDNA) in hormone receptor-positive&#x2F;HER2-negative (HR+&#x2F;HER2-) early breast cancer (EBC)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566245-4000px.png">(PO1-20-03) Acupuncture for Preventing Progression of Taxane-Induced PeripheralNeuropathy (ATP): A Phase II Randomized</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566269-4000px.png">(PO1-20-04) STX-478-101: A phase 1&#x2F;2</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566286-4000px.png">(PO1-20-05) SURVIVE study â?a multicenter</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566306-4000px.png">(PO1-20-06) Phase 2 study of novel HER2-targeting</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566160-4000px.png">(PO1-20-07) Valosin-containing protein (VCP)&#x2F;p97: A novel breast cancer susceptibility gene?</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566215-4000px.png">(PO1-20-08) Primary breast implant-associated squamous cell carcinoma with subsequent TEMPUS testing and failure of immunotherapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566294-4000px.png">(PO1-20-09) A rare unilateral expression of hand-foot syndrome: a case report</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567534-4000px.png">(PO1-20-10) Wernicke Encephalopathy Syndrome in Metastatic Breast Cancer â?A Diagnostic Dilemma or An Underdiagnosed Entity</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566381-4000px.png">(PO1-20-11) Delay in Diagnosis of Locally Advanced Breast Cancer during Lactation âCase Reportâ?https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566398-0100px.png</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2612486-4000px.png">(PO1-20-13) TROPION-Breast04: A phase 3 study of neoadjuvant datopotamab deruxtecan (Dato-DXd) + durvalumab followed by adjuvant durvalumab vs the standard of care in treatment-naive early-stage triple negative or HR-low&#x2F;HER2â?breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2595014-4000px.png">(PO1-21-01) A Case of High Grade Metastatic Encapsulated Papillary Carcinoma and a Look at Current Treatment Guidelines</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566153-4000px.png">(PO1-22-02) Optimal intra-fraction PTV margins for patients receiving stereotactic partial breast radiation (SPBI) using cone beam adaptive radiation therapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566091-4000px.png">(PO1-22-03) Radiation Toxicity and Treatment Outcomes in Breast Cancer Patients with ATM Pathogenic and VUS Mutations: Implications for Personalized Therapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566125-4000px.png">(PO1-22-04) Cosmetic results of the breast in patients treated with Five Fraction Accelerated Partial Breast Irradiation for early stage breast cancer: retrospective review comparing Daily versus Every Other Day Treatment.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566126-4000px.png">(PO1-22-05) Radiation Therapy Toxicities and Survival Outcomes in Monoallelic ATM Variant Carriers with Non-Metastatic Breast Cancer: A Retrospective Analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566134-4000px.png">(PO1-22-06) Pre-operative radiotherapy followed by mastectomy and breast reconstruction â?a systematic review of oncological and reconstructive outcomes</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566078-4000px.png">(PO1-22-08) Ductal Lavage versus Oral Corticosteroids in Patients with Idiopathic Granulomatous Mastitis: A Multicenter</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566383-4000px.png">(PO1-22-09) Current margin assessment practice for breast-conserving surgery in China: a single institution audit</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566122-4000px.png">(PO1-22-10) Long term outcomes of breast cancer patients with local recurrence after mastectomy undergoing immediate breast reconstruction: A retrospective multi-institutional study of 4153 cases</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566146-4000px.png">(PO1-22-11) Use of magnetic tracer and magnetic resonance imaging for sentinel lymph node detection after breast cancer recurrence and previous axillary surgery: The SentiRecur feasibility study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566152-4000px.png">(PO1-23-01) A novel nomogram for predicting the possibility of omitting axillary lymph node dissection after neoadjuvant chemotherapy for clinical node-positive breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566197-4000px.png">(PO1-23-02) Magnetic seeds used for the detection of target lymph nodes after neoadjuvant therapy for early breast cancer â?a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566198-4000px.png">(PO1-23-03) Management and risk of upgrade of Atypical Ductal Hyperplasia in the breast â?a population-based retrospective cohort analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566199-4000px.png">(PO1-23-04) The IBRAnet localisation study; a UK National multi-centre cohort study comparing the safety and effectiveness of guidewire</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566200-4000px.png">(PO1-23-05) Exploratory clinical trial of preoperative non-invasive localization before surgery in breast cancer patients using augmented reality technology</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566233-4000px.png">(PO1-23-07) The effect of intra-operative margin assessment during breast conserving surgery for breast cancer in a Dutch cohort</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566287-4000px.png">(PO1-23-08) Exosome-based delivery of microRNAs confers adriamycin-resistance to sensitive cells through modulating the immune and metabolism-related gene PTEN in HER2-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566209-4000px.png">(PO1-23-09) A bedside-to-bench translational analysis demonstrates that NF1 alterations promote CDK4&#x2F;6 inhibitor (CDK4&#x2F;6i) resistance in hormone receptor-positive (HR+) metastatic breast cancer (MBC)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566263-4000px.png">(PO1-23-11) Differential m6A modification identified by direct RNA sequencing in endocrine- resistant and sensitive breast cancer cells</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566175-4000px.png">(PO1-24-01) ADAR1 drives ribosomal biogenesis by regulating NOP14 and stabilizing FBL-NOP58 complex in breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566242-4000px.png">(PO1-24-02) Enhancement of TGF-Î² Receptor Inhibitor Efficacy through CD44 Suppression in Claudin-low Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566248-4000px.png">(PO1-24-03) The clinicopathological and prognostic significance of HER2-low breast cancer: A comparative analysis between HER2-low and HER2-zero subtypes</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566303-4000px.png">(PO1-24-04) Gedatolisib</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566354-4000px.png">(PO1-24-05) EZH2 histone methyltransferase activity promotes spindle metaplastic breast carcinoma metastasis and is induced by CCN6 knockout &#x2F; b-catenin &#x2F; TCF axis.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566369-4000px.png">(PO1-24-06) Prolactin Hormone-Induced Mammary Differentiation and Anti-tumorigenic Role in Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566394-4000px.png">(PO1-24-07) LYSOSOMAL-ASSOCIATED TRANSMENBRANE 4B (LAPTM4B) AS POTENTIAL BIOMARKER IN BREAST CANCER</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566429-4000px.png">(PO1-24-08) Targeting of HER3 potentiates the antitumor activity of paclitaxel against triple negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566076-4000px.png">(PO1-24-10) B cellâmediated immunity predicts survival of patients with ER-positive breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566083-4000px.png">(PO1-24-11) Distinct patterns of MHC class I</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566096-4000px.png">(PO1-24-12) Investigating the immunological function of alpha-2-glycoprotein 1</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566195-4000px.png">(PO1-25-04) PTN-positive luminal progenitors induce angiogenesis and metastasis in inflammatory breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566196-4000px.png">(PO1-25-05) Adipose-enriched peri-tumoral stroma prognosticates poorer survival in breast cancers</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566201-4000px.png">(PO1-25-06) Integrated analysis of single-cell RNA and VDJ-sequencing data to identify T cell marker expressed on antigen-specific T cells</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566074-4000px.png">(PO1-25-08) Evaluating the role of CDK4&#x2F;6 inhibition on STAT3 activation in a transgenic mouse model of HER2-positive breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566739-4000px.png">(PO1-25-11) Deciphering biological differences between normal breast tissues in men and women using single cell sequencing and in vitro modeling</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567030-4000px.png">(PO1-26-01) Leveraging Clinicopathological Factors and Deep Learning-Based Morphometrics for PDX Engraftment Success Prediction in Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567224-4000px.png">(PO1-26-04) Patient-derived organotypic tissue cultures for organoid isolation and probing unique metabolic features of individual breast cancer patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567263-4000px.png">(PO1-26-05) Animal Study Compares CAR T cell Exhaustion &amp; Ability to Kill Low Antigen expressing breast cancer cells among three CAR constructs including one with 1XX mutations</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567410-4000px.png">(PO1-26-06) The effect of localized radiotherapy in combination with chemoimmunotherapy in a humanized triple-negative breast cancer mouse model</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571003-4000px.png">(PO1-27-01) Comparing the Efficacy and Safety of TQB2440 versus the Reference Pertuzumab for the Treatment of HER2-Positive Early or Locally Advanced Breast Cancer: A Multicenter</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571035-4000px.png">(PO1-27-03) Studies on factors for pathological complete response after neoadjuvant chemotherapy in relation to HER2 status in primary breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571057-4000px.png">(PO1-27-05) De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab in HER2-positive early breast cancer (HELEN-006):a randomized</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571044-4000px.png">(PO1-27-06) HER2 Amplification Level and Focal&#x2F;Broad Region Size as Predictors of Treatment Response in Neoadjuvant Chemotherapy and Anti-HER2 Therapy for HER2-Positive Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571023-4000px.png">(PO1-27-07) Is HER2-low a biologically distinct breast cancer (BC) subtype? Prognosis and pathological complete response rate after neoadjuvant treatment (NAT) in early breast cancer (BC) HER2 negative.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2570995-4000px.png">(PO1-27-09) TRIPTORELIN (11.25MG) vs TRIPTORELIN (3.75MG) IN PREMENOPAUSAL WOMEN WITH HIGH-RISK EARLY STAGE BREAST CANCER RH(+) and HER2(-) REAL WORLD EXPERIENCE. TRIPTO3 RESULTS</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2570996-4000px.png">(PO1-27-10) Adjunctive statistical standardization of quantitated machine image analysis of Estrogen and Progesterone Receptors: CCTG MA.27 trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571070-4000px.png">(PO1-27-11) Survival Benefit of Adjuvant Endocrine Therapy in Patients with Estrogen Receptor Low-Positive Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2570997-4000px.png">(PO1-28-01) MammaPrint and BluePrint identify racial disparities among women with HR+HER2- early-stage breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571006-4000px.png">(PO1-28-03) Impact of the Oncotype DXÂ® test over time and association with clinicopathological characteristics of Peruvian patients with early breast cancer: Experience in the last 15 years</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571007-4000px.png">(PO1-28-04) PILHLE-001: neoadjuvant pyrotinib combined with chemotherapy in HR-positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571055-4000px.png">(PO1-28-06) Development of a plasma-based real-time qPCR gene expression assay for targeted screening and diagnosis of early-stage breast cancer.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571009-4000px.png">(PO1-28-07) Neoadjuvant docetaxel plus cisplatin versus docetaxel plus doxorubicin and cyclophosphamide in early-stage triple-negative breast cancer (HNBC-001): results from a multicenter</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571046-4000px.png">(PO1-28-08) The Efficacy and Safety Results of Neoadjuvant Phase II study of Anlotinib plus Sintilimab Combined with Chemotherapy in Triple-negative Breast Cancer (NeoSACT)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571068-4000px.png">(PO1-28-09) Rethinking the value of pathologic complete response rate for the survival outcomes of early triple-negative breast cancer treated with neoadjuvant chemotherapy: a systematic review and network meta-analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571086-4000px.png">(PO1-28-10) Tumor Infiltrating Lymphocytes identify patients with stage I TNBC with excellent outcome without chemotherapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571071-4000px.png">(PO1-29-02) Two and a half years follow-up data of HER2-targeted bispecific antibody KN026 combined with docetaxel as first-line treatment for HER2-positive recurrent&#x2F;metastatic breast cancer.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571004-4000px.png">(PO1-29-03) Efficacy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571002-4000px.png">(PO1-29-04) Spatial tumor microenvironment profiling identifies immune features that correlate with response to T-DXd treatment in patients with metastatic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566414-4000px.png">(PO2-01-01) Biophysical simulation using DCE-MRI to forecast response to NAT in HER2+ patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2570993-4000px.png">(PO2-01-03) Efficacy of dose-dense and anthracycline-free regimens in neoadjuvant chemotherapy of HER2-positive breast cancer: a single-center matched-cohort study. Preliminary results.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566600-4000px.png">(PO2-01-04) Efficacy and safety of anti-HER2 therapy in neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566647-4000px.png">(PO2-01-05) Neoadjuvant pyrotinib plus trastuzumab</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567006-4000px.png">(PO2-01-06) Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in HER2+ early-breast cancer (EBC).</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2570994-4000px.png">(PO2-01-07) Real-world efficacy of dual HER2-blockade in combination with anthracycline-containing and anthracycline-free neoadjuvant treatment in early breast cancer (BC).</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566355-4000px.png">(PO2-01-08) Differential HOXB13 gene expression and promoter methylation analysis in breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566360-4000px.png">(PO2-01-09) Patient preferences for CDK4&#x2F;6 inhibitor treatments in HR+&#x2F;HER2â?early breast cancer: a discrete choice survey study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566422-4000px.png">(PO2-01-11) Demographic</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566448-4000px.png">(PO2-01-12) Preoperative cryoablation in 52 Her2- Luminal invasive ductal carcinomas â?2cm. Analysis of the tumor specimen.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566467-4000px.png">(PO2-01-13) Clinico-Pathological and Molecular Characterization of Early Hormone Receptor-Positive Breast Cancer in Young Women</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566469-4000px.png">(PO2-01-14) Development of Artificial Intelligence-based Machine Learning Models for Predicting Survival In Hormone-Receptor-Positive&#x2F;HER2-Negative Early Breast Cancer undergoing Neoadjuvant Chemotherapy.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566485-4000px.png">(PO2-02-01) Online Virtual Patient Simulation CME Improves Clinical Decision-Making In The Management Of Patients With HR+&#x2F;HER2- Early Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566490-4000px.png">(PO2-02-02) BREAst Cancer Personalized NuTrition (BREACPNT): dietary intervention in HR+ breast cancer patients treated with endocrine therapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566520-4000px.png">(PO2-02-03) Clinical and pathological factors associated with Oncotype DXÂ® 21-Gene recurrence score in patients diagnosed with early stage breast cancer in a low-middle income country</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566534-4000px.png">(PO2-02-04) The Impact of Statins on Breast Cancer Specific Mortality in a Diverse Patient Population with Stage I-III Hormone Receptor Positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566557-4000px.png">(PO2-02-05) CDK4&#x2F;6 inhibitor dalpiciclib combined with letrozole as neoadjuvant therapy in postmenopausal patients with hormone receptor-positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566513-4000px.png">(PO2-02-07) Clinicopathological Features and Prognostic Role of HER2 Low in Early Breast Cancer: A real world study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566527-4000px.png">(PO2-02-09) Pathological complete response to neoadjuvant systemic therapy and its predictive factors among early breast cancer subtypes: the emerging role of HER2</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566531-4000px.png">(PO2-02-10) Predicting the feasibility of breast conserving surgery using pre-treatment standard of care DCE-MRI: a novel clinical decision support tool for breast cancer surgical planning</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566532-4000px.png">(PO2-02-11) Radiomics and an Erosion Model to Predict Post-Neoadjuvant Therapy Tumor Characteristics for Personalized Breast Cancer Treatment</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566577-4000px.png">(PO2-02-13) A Mechanical Conditioning gene expression (MeCo) score detects the patients that benefit from neoadjuvant anti-fibrotic therapy in early HER2-negative breast cancer (HER2negBC).</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566585-4000px.png">(PO2-02-14) Development of a multi-institutional</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566610-4000px.png">(PO2-03-01) Personalized 3D tumor models drive shared decision-making in early breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566614-4000px.png">(PO2-03-02) Technology-enabled identification of low-risk breast cancer survivors for personalized survivorship care</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566625-4000px.png">(PO2-03-03) The Significance of Cavity Shave Margins in Breast Carcinoma on Margin Status and Re-excision Rates</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566567-4000px.png">(PO2-03-05) Neoadjuvant anthracycline followed by Toripalimab combined with nab-paclitaxel in patients with stage IIA-IIIC triple negative breast cancer (NeoTENNIS): efficacy and safety results of a phase II study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566611-4000px.png">(PO2-03-06) Pathological complete response with chemotherapy and immune checkpoint inhibition in triple negative inflammatory breast cancer (TN-IBC)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566698-4000px.png">(PO2-03-09) Cost-effectiveness analysis of RAD51 functional biomarker for platinum sensitivity in the GeparSixto trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566744-4000px.png">(PO2-03-10) Association of pathologic complete response with the 27-gene IO score and week 3 IOpath response following neoadjuvant pembrolizumab +&#x2F;- intralymphatic cytokines in the neoIRX trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566800-4000px.png">(PO2-03-11) A novel peripheral CD4+ T cell immune network associated with response to PD-1 inhibitor in early-stage triple negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566829-4000px.png">(PO2-03-12) Dose-Dense Doxorubicin plus Cyclophosphamide (ddAC) and Impact of Chemotherapy Sequence in a Modified KEYNOTE-522 Regimen for Neoadjuvant Treatment of Triple Negative Breast Cancer: Real World Experience</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566433-4000px.png">(PO2-04-01) Predictors of exceptional response to first line HER2-targeted therapy for metastatic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566493-4000px.png">(PO2-04-03) BL-M07D1</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566547-4000px.png">(PO2-04-04) Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and&#x2F;or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566552-4000px.png">(PO2-04-05) FINAL OUTCOME ANALYSIS FROM THE PHASE II TUXEDO-1 TRIAL OF TRASTUZUMAB-DERUXTECAN IN HER2-POSITIVE BREAST CANCER PATIENTS WITH ACTIVE BRAIN METASTASES</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566692-4000px.png">(PO2-04-06) Investigation of the genomic evolution of HER2-positive breast cancer following progression on dual HER2-targetted therapy with Trastuzumab and Tucatinib.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566721-4000px.png">(PO2-04-07) Efficacy and Safety of First-line Therapy in Patients with HER-2 positive Advanced Breast Cancerï¼A network Meta-analysis of Randomized Controlled Trials</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566727-4000px.png">(PO2-04-08) Translational insights from a phase 1</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566288-4000px.png">(PO2-04-09) Combination of the PLK1 Inhibitor Onvansertib and the PI3KÎ± Inhibitor Alpelisib Overcomes Palbociclib Resistance in PIK3CA-mutated HR+ Breast Cancer.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566289-4000px.png">(PO2-04-10) Effect of Alpelisib Dose Modification for AE Management on Progression-Free Survival and Treatment Duration in SOLAR-1 and BYLieve Clinical Trials</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567191-4000px.png">(PO2-04-12) From Clinical Trials to Clinical Practice; Real World Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566312-4000px.png">(PO2-04-14) Dual Inhibition of WEE1 and PKMYT1 Synergistically Overcomes CDK4&#x2F;6 Inhibitor Resistance in Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566313-4000px.png">(PO2-05-01) Famitinib</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566317-4000px.png">(PO2-05-02) Real-world experience of patients receiving treatment for hormone receptor-positive &#x2F;human epidermal growth factor receptor-2 negative metastatic breast cancer: A global analysis of symptoms and side effects</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566318-4000px.png">(PO2-05-03) Costs associated with adverse events in patients receiving treatment for hormone receptor positive&#x2F;human epidermal growth factor receptor-2 negative metastatic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566332-4000px.png">(PO2-05-04) ELEVATE: A phase 1b&#x2F;2</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566333-4000px.png">(PO2-05-05) ELECTRA: An open-label</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566338-4000px.png">(PO2-05-06) Palbociclib in advanced hormone receptor positive breast cancer: A real world study in South America</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566348-4000px.png">(PO2-05-07) Which treatment is done in patients with metastatic breast cancer who received a prior treatment with CDK4&#x2F;6 inhibitors? A real-world experience in a single italian Institution</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566367-4000px.png">(PO2-05-08) ISM5043</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566371-4000px.png">(PO2-05-10) ‘I am Still Alive’: An Interpretative Phenomenological Analysis of Older Women Living with Metastatic Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566388-4000px.png">(PO2-05-11) Patient Perspectives on the Value of Stereotactic Body Radiotherapy (SBRT) in the Management of Breast Cancer: The PERSPECTIVE Study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566474-4000px.png">(PO2-05-12) Retrospective analysis on therapeutic efficacy and predictive indicators of eribulin plus anti-angiogenic drugs for metastatic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566496-4000px.png">(PO2-05-13) HER2 status presented an unstable switching from primary to recurrent breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566498-4000px.png">(PO2-05-14) Prognosis and clinicopathological characteristics of HER2-negative metastatic breast cancers with low expression of hormone receptors: real world evidence from the French ESME cohort.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566525-4000px.png">(PO2-06-01) Validity of patient-reported data from long-term survivors of metastatic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566618-4000px.png">(PO2-06-02) Characteristics and Treatment Patterns of de novo Oligometastatic Stage IV Breast Cancer: A Single-Center Retrospective Cohort Study.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566629-4000px.png">(PO2-06-03) Meta-Analysis of Clinical Characteristics and Outcomes in Breast Cancer Patients with Visceral Crisis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566648-4000px.png">(PO2-06-04) Prospective study on eribulin efficacy in advanced and metastatic breast cancer: changes in TGF-Î² compared to other standard chemotherapy agents (KBCSG-TR 2018</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566668-4000px.png">(PO2-06-05) Neutrophil-to-lymphocyte ratio (NLR) Predict the Outcome Significance for Primary Tumor Surgery in Patients with De novo stage â?Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566685-4000px.png">(PO2-06-06) Effectiveness and prognostic predictors of primary systemic therapy for de-novo Stage IV breast cancer - Supplementary analysis of JCOG1017 PRIM-BC</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566425-4000px.png">(PO2-06-07) A Randomized Phase II Comparison of Single-Agent Carboplatin versus the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple Negative Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566428-4000px.png">(PO2-06-08) Suppression of GATA2&#x2F;3-FOXA1-HER3 Axis by Histone Deacetylase (HDAC) Inhibitors shows Antitumor Activity in Basal-like Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566435-4000px.png">(PO2-06-09) A prospective phase 2 study on efficacy and safety of AK105</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566461-4000px.png">(PO2-06-10) Prevalence of genomic alterations in Xerna tumor microenvironment subtypes in triple negative breast cancer patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566477-4000px.png">(PO2-06-11) A phase II randomized trial of gemcitabine plus cisplatin(GP) vs gemcitabine plus carboplatin (GC) as the first-line treatment for patients with metastatic triple-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566564-4000px.png">(PO2-06-12) Patients with metastatic triple-negative breast cancer who receive trilaciclib prior to cytotoxic chemotherapy exhibit improved survival after receiving subsequent anticancer therapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566582-4000px.png">(PO2-06-13) Promising clinical performance of 89Zirconium-labelled Girentuximab PET-CT for imaging metastatic triple negative breast cancer patients (OPALESCENCE)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571032-4000px.png">(PO2-06-14) Kynurenine induces senescence reprogramming to promote metastasis in young triple-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566353-4000px.png">(PO2-07-01) Predicted Circadian-related Transcription Factors in Human Breast Cell LinesâA key to understanding breast cancer pathology?</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566503-4000px.png">(PO2-07-03) Retrospective Validation Study of an Artificial Neural Network-Based Preoperative Decision-Support Tool for Noninvasive Lymph Node Staging (NILS) in Women with Primary Breast Cancer (ISRCTN14341750)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566533-4000px.png">(PO2-07-04) Applying the Alliance Trial Guidelines in Multi-focal Breast Disease Using an Artificial Intelligence Computational Platform: Economic Analysis and Cosmetic Sensitivity</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566561-4000px.png">(PO2-07-05) Deep learning model for automated quantification of HER2 expression in invasive breast cancers from immunohistochemical whole slide images</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566342-4000px.png">(PO2-07-07) The role of PET imaging with [18F]16Î±-fluoro-17Î²-fluoroestradiol in predicting response to endocrine therapies in patients with breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566484-4000px.png">(PO2-07-08) The efficacy of an MRI&#x2F;US fusion technique for MRI-detected lesions previously undetected by conventional B-mode second-look US</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566351-4000px.png">(PO2-07-09) Early stage invasive lobular breast cancer is underestimated on conventional imaging including MRI</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566456-4000px.png">(PO2-07-12) Analysis Of Malignity Rates Of Percutaneous Biopsy In Lymph Nodes Of Breast Cancer Patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566419-4000px.png">(PO2-08-01) Universal Multi-Gene Panel Testing of Newly Diagnosed Breast Cancer Patients in a Community Healthcare System</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566455-4000px.png">(PO2-08-03) Developing a polygenic risk score for precision prevention of estrogen receptor-positive (ER+)&#x2F;HER2- breast cancer in Brazilian women</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566457-4000px.png">(PO2-08-04) Unraveling alterations in the pre-neoplastic breast microenvironment of BRCA1&#x2F;2 mutation carriers using spatial transcriptomics</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566504-4000px.png">(PO2-08-05) ERBB2 mutated breast cancer detected by next generation sequencing: integrated analysis based on real-world data and The Cancer Genome Atlas</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566138-4000px.png">(PO2-08-06) Metformin may improve the outcome of patients with breast cancer and type 2 diabetes mellitus through the effect of tumor immune microenvironment.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566510-4000px.png">(PO2-08-07) Evaluating chemotherapy receipt and candidacy for PARP inhibitors in germline BRCA1&#x2F;2 carriers with early and locally advanced breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566516-4000px.png">(PO2-08-09) Prevalence of germline genetic variants in breast cancer susceptibility genes among patients with metaplastic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566519-4000px.png">(PO2-08-10) Effect of 6 months of bazedoxifene + conjugated estrogens on body composition and insulin resistance.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566642-4000px.png">(PO2-08-11) The MAGIC study: Universal whole genome tumour and germline sequencing of newly diagnosed breast cancer identifies a high proportion of ER+ BRCA-like tumours</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566716-4000px.png">(PO2-09-04) Changes in an artificial intelligence model score for breast cancer detection (Transpara) with tamoxifen and aromatase inhibitor treatment</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566395-4000px.png">(PO2-09-05) Building genomic and transcriptomic data among African American and Black patients with triple-negative inflammatory breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566400-4000px.png">(PO2-09-06) Interaction of racial disparities on outcomes and toxicities associated with treatment of HER2+Breast Cancer- a TrinetX Database study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566427-4000px.png">(PO2-09-07) Neighborhood Disadvantage and Social Adversity in Breast Cancer Patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566431-4000px.png">(PO2-09-08) Biological and non-biological predictors of breast cancer disease-free survival among young Black females</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566226-4000px.png">(PO2-09-09) Racial&#x2F;Ethnic Differences in Survival of Male Patients with Stage I-III Breast Cancer by Hormone Receptor Status Using Real-World Data</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566468-4000px.png">(PO2-09-10) Addressing Breast Cancer Disparities: Co-Creating Digital Interventions with Patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566537-4000px.png">(PO2-09-11) Breast Cancer Care Disparities in Sexual Minority Women: An Analysis of the National Institutes of Health All of Us Research Program</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566687-4000px.png">(PO2-09-12) The magnitude and temporal variations of socioeconomic inequalities in quality of life after early breast cancer: results from the multicentric French CANTO cohort</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566590-4000px.png">(PO2-10-01) Discrimination</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566607-4000px.png">(PO2-10-02) ‘Sharing Our Own Experience’: A Qualitative Study of Black Women Diagnosed with Triple-Negative Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566656-4000px.png">(PO2-10-03) Clinical characteristics and survival trends of male breast cancer in the United States: A propensity score matched analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566580-4000px.png">(PO2-10-04) Clinicopathological Characteristics and Factors Associated With Screening and Late-Stage Diagnosis in Patients With Breast Cancer in Latin America: The LATINA Study (LACOG 0615&#x2F;MO39485)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566745-4000px.png">(PO2-10-05) The Impact of Socioeconomic Factors on Breast Cancer Diagnosis in Latin America: The LATINA study (LACOG 0615&#x2F;MO39485)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566556-4000px.png">(PO2-10-06) The Rising Burden of Contraception Requirements in Breast Cancer Clinical Trials: Time for Change?</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566630-4000px.png">(PO2-10-08) Contemporary HER2-Positive MBC Treatment Recommendations Among Community Healthcare Professionals: Analysis of an Online Interactive Decision Support Tool</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566738-4000px.png">(PO2-10-09) Professional Support for Eating and Nutrition among Women Living with Breast Cancer: Implications for Mental Health and Quality of Life</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566760-4000px.png">(PO2-10-10) Developing a Continuum of Care Model to Address Healthcare Disparities in Breast and Cervical Cancer: The Promise Fund’s Approach</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566771-4000px.png">(PO2-10-11) Impact of COVID-19 Pandemic on the Disease Volume</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566780-4000px.png">(PO2-10-12) The devil is in the details: Workflow analysis of breast cancer treatment decision making and implications for decision support design</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566807-4000px.png">(PO2-11-01) Prevalence of Nonadherence to Endocrine Therapy and Cardiovascular Medications Among Breast Cancer Survivors.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566826-4000px.png">(PO2-11-02) Incidence</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566451-4000px.png">(PO2-11-03) A long-term follow-up of patients who interrupted endocrine therapy to become pregnant following breast cancer surgery</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566452-4000px.png">(PO2-11-04) Assessing quality of Life in breast cancer patients undergoing mHealth mobile monitoring: A descriptive Analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566494-4000px.png">(PO2-11-05) Pregnancy Trends Following Breast Cancer Treatment: Insights from a Large Single-Center Experience</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566848-4000px.png">(PO2-11-06) Anti-MÃ¼llerian hormone in Young women with breast CAncer to predict permanent loss of ovarian function after chemotherapy and anti-HER2 therapy (AMYCA): a biomarker analysis of the BETH and KAITLIN trials</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566621-4000px.png">(PO2-11-07) Early Integration of Exercise into Breast Cancer Care: The MSK Healthy Living Program</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566622-4000px.png">(PO2-11-08) Divorce and marital dissolution after Breast Cancer diagnosis in young breast cancer survivors in Mexico.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566637-4000px.png">(PO2-11-09) European Lobular Breast Cancer Advocates: Bridging the Geographical Gaps in Lobular Breast Cancer Education and Awareness</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566639-4000px.png">(PO2-11-10) Can chemotherapy-induced peripheral neuropathy be predicted? Implications for future prevention and treatment of this side-effect.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566651-4000px.png">(PO2-11-11) ‘Whoâs gonna take care of my babies?’ The Impact of Children on Treatment Decisions for Women with Metastatic Breast Cancer: A qualitative analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566694-4000px.png">(PO2-11-12) The power of storytelling to heal</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566737-4000px.png">(PO2-12-01) Five-year quality of life (QOL) trajectories among young breast cancer (BC) survivors</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566785-4000px.png">(PO2-12-02) Frailty among long-term breast cancer survivors</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566830-4000px.png">(PO2-12-03) Home-based Resistance Exercise Improves Fatigue and Functional Strength in Female Breast Cancer Survivors Post Chemotherapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566833-4000px.png">(PO2-12-04) Suboptimal adherence to adjuvant endocrine therapy (ET) in Brazilian women with early-stage estrogen receptor-positive (ER+) breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566375-4000px.png">(PO2-12-05) Scalp Cooling with the Capelli System to Reduce Doxorubicin-induced Alopecia in Patients with Localized Breast Cancer: A Phase 2 Randomized Controlled Trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566489-4000px.png">(PO2-12-06) Comparative Study on Bone Mineral Density in Premenopausal Patients with Estrogen Receptor-Positive Breast cancer in ASTRRA study: a 5-year follow-up study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566491-4000px.png">(PO2-12-07) Risk of anaphylaxis associated with the use of pertuzumab or other biologics with potential for use outside the hospital</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566512-4000px.png">(PO2-12-08) Increased burden of genetic variants in idiopathic cardiomyopathy genes is associated with cancer therapy-related cardiomyopathy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566529-4000px.png">(PO2-12-09) Insomnia</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566586-4000px.png">(PO2-12-11) Ocular Toxicity of Tamoxifen in Patients with Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566615-4000px.png">(PO2-12-12) REaCT 5G: A randomized study comparing bone pain after 5 days of filgrastim or one day of pegfilgrastim for primary febrile neutropenia prophylaxis during neo-&#x2F;adjuvant chemotherapy for early breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566741-4000px.png">(PO2-13-01) Weight change in early breast cancer-based baseline body mass index and treatment</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567221-4000px.png">(PO2-13-02) Detection of SPEN mutations in advanced breast cancer by circulating tumor cell-free DNA</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566479-4000px.png">(PO2-13-03) Spatial HER2 heterogeneity on HER2-PET in HER2-low and negative disease: potential biomarker for antibody-drug conjugate effect</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566488-4000px.png">(PO2-13-05) Deciphering pregnancy-associated breast cancer: distinctive molecular profile and clinical implications from GEICAM&#x2F;2017-07 EMBARCAM study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566502-4000px.png">(PO2-13-06) Analysis of Antibody Response to SV-BR-1-GM Therapeutic Vaccine in Breast Cancer Patients Using Human Protein Microarrays: Potential Correlations with Therapy Response</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566511-4000px.png">(PO2-13-07) SMARCA2 compensation of SMARCA4 loss mediates adaptive resistance to neoadjuvant systemic therapy in triple-negative breast cancer: paired transcriptomic analysis of pre- and post-treatment samples from NeoSTOP and NeoPACT</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566518-4000px.png">(PO2-13-08) Cell-free orphan noncoding RNAs and AI enable early detection of invasive breast cancer and ductal carcinoma in-situ</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566846-4000px.png">(PO2-13-09) Delayed alopecia among breast cancer survivors</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566187-4000px.png">(PO2-13-10) Predicting outcomes in locally advanced breast cancer through profiling post-neoadjuvant tissue-based minimal residual disease.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566559-4000px.png">(PO2-13-11) High circulating tumor DNA (ctDNA) concentration was associated with shorter progression free survival in patients with metastatic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566560-4000px.png">(PO2-13-12) Serum Thioredoxin 1 Enhances Breast Cancer Detection in Mammography and Breast Ultrasound</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566565-4000px.png">(PO2-14-02) Clinical significance of urinary microRNA expression in primary breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566569-4000px.png">(PO2-14-03) Novel Metrics of HER2 Heterogeneity in HER2-Positive and HER2-Low Breast Cancer via High Dimensional Multiplexed Immunofluorescence Spatial Profiling</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566575-4000px.png">(PO2-14-04) Circulating tumor DNA after neoadjuvant chemotherapy is a better prognostic test than Residual Cancer Burden in patients with triple negative breast cancer and residual tumor</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566594-4000px.png">(PO2-14-05) COMPARISON OF HER2 mRNA PCR LEVELS AND IMMUNOHISTOCHEMISTRY (IHC) IN HORMONE RECEPTOR POSITIVE (HR+) &#x2F; HER2 NEGATIVE (HER2-) EARLY BREAST CANCER.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566598-4000px.png">(PO2-14-06) CIRCULATING TUMOR DNA DYNAMICS IN THE FIRST TREATMENT LINE OF THE SONIA TRIAL</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566612-4000px.png">(PO2-14-08) Development and characterization of breast cancer organoids representing epithelial heterogeneity and drug response</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566613-4000px.png">(PO2-14-09) Baseline genomic alterations and the activity of lasofoxifene (LAS) plus abemaciclib (Abema) in patients with ER+&#x2F;HER2- metastatic breast cancer (mBC): the ELAINE 2 study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566623-4000px.png">(PO2-14-10) A selective MCL-1 inhibitor AZD5991 showed tumor regression in a triple-negative inflammatory breast cancer xenograft model</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566636-4000px.png">(PO2-14-11) Proteogenomic approaches for the identification of NF1&#x2F;neurofibromin-depleted estrogen receptor positive breast cancers for targeted treatment</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566646-4000px.png">(PO2-14-12) Accurate quantification of slide-level HER2 scores in breast cancer using a machine-learning model</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566653-4000px.png">(PO2-15-01) EZH2 protein expression in early hormone receptor positive HER2 negative breast cancer with high recurrence score</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566669-4000px.png">(PO2-15-03) Platelet-to-lymphocyte ratio in patients with metastatic breast cancer treated with eribulin.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566670-4000px.png">(PO2-15-04) Fas&#x2F;FasL expression on circulating tumor and immune cells in the peripheral blood of patients with metastatic breast cancer (BC): correlation with clinical outcome</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566691-4000px.png">(PO2-15-06) ctDNA-based DNADX in hormone receptor-positive and HER2-negative (HR+&#x2F;HER2-) advanced breast cancer following endocrine therapy and CDK4&#x2F;6 inhibition: a correlative analysis from the randomized phase 2 PARSIFAL trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566699-4000px.png">(PO2-15-07) HER2DX genomic assay in triple-negative breast cancer (TNBC) patients treated with 12-weeks of neoadjuvant chemotherapy: a correlative analysis from WSG-ADAPT-TN phase II trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566700-4000px.png">(PO2-15-08) Exploring Essential Immune Genes Linked to Pathological Complete Response and Survival in Early-Stage Triple-Negative Breast Cancer (TNBC) after Chemotherapy Treatment</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566701-4000px.png">(PO2-15-09) Immune related cell fraction in peripheral blood and outcomes of advanced breast cancer patients treated with Eribulin</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566704-4000px.png">(PO2-15-10) Identifying new immune-related biomarkers in TNBC with a look at PD-L1 cell-autonomous role.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566706-4000px.png">(PO2-15-11) Kinetic Analysis of [5-11C] glutamine PET tracer data in breast cancer: Preclinical studies in mouse models</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566707-4000px.png">(PO2-15-12) Novel Transcriptomic Classification System Unveils HER2-Low Breast Tumors</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566726-4000px.png">(PO2-16-01) Molecular correlates of drug response to guide therapy in triple-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566734-4000px.png">(PO2-16-02) RBsig gene-expression signature in patients with endocrine resistant metastatic breast cancer treated with palbociclib and fulvestrant in the PYTHIA trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566755-4000px.png">(PO2-16-03) ESR1 genomic alterations (GAs) and coexistent putative resistance alterations in comprehensive genomic profiling (CGP) of metastatic breast cancer (MBC)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566763-4000px.png">(PO2-16-04) Proteogenomic characterization of non-luminal A versus luminal A breast cancer tumor cells enriched by laser microdissection</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566767-4000px.png">(PO2-16-05) ESR1 mutations (ESR1mut) in HR(+)HER2(-)patients with metastatic breast cancer (MBC): prevalence along treatment course and predictive value for endocrine therapy (ET) resistance in real-world practice</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566408-4000px.png">(PO2-16-06) Treatment Patterns of Neoadjuvant Therapy in Chinese Patients with HR-Positive&#x2F;HER2-Positive Early or Locally Advanced Breast Cancer: A Real-World Study Using NCID Data in 2019-2022</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566416-4000px.png">(PO2-16-07) Real-world eligibility for adjuvant CDK4&#x2F;6 inhibitors among patients without genomic risk for chemotherapy: a GBECAM multicenter retrospective study.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566123-4000px.png">(PO2-16-08) Adjuvant Treatment Selection for County-Level Patients with HR+&#x2F;HER2- Early Breast Cancer in a Real-Life Setting in China</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566424-4000px.png">(PO2-16-09) Dose-dense versus 3-weekly AC during Neoadjuvant Chemoimmunotherapy for Early-Stage Triple-Negative Breast Cancer (TNBC): a Real-World Safety and Efficacy Data Analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566442-4000px.png">(PO2-16-10) Characterising HER2-low status in metastatic breast cancer: a real-world retrospective study of patients at a metropolitan cancer centre in Australia.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566466-4000px.png">(PO2-16-11) Real-World Data of Neuroendocrine Neoplasms of Breast</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566471-4000px.png">(PO2-16-12) Real world evidence of neoadjuvant chemotherapy for breast cancer treatment in a Brazilian multicenter cohort: correlation of pathological complete response and overall survival</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566480-4000px.png">(PO2-17-01) Impact of the introduction of CDK4&#x2F;6 inhibitors on treatment duration in patients with HR+</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566492-4000px.png">(PO2-17-03) Patient reported outcomes (PROs) and survival with toremifene versus aromatase inhibitors (AI) in patients with moderate&#x2F;high-risk premenopausal hormone receptor (HR)-positive breast cancer: A real-world study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566528-4000px.png">(PO2-17-05) Pharmacy fills but not baseline distress or other clinical factors can identify those at high risk for early adjuvant endocrine therapy discontinuation</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566530-4000px.png">(PO2-17-06) Real world treatment patterns and clinical outcomes by germline BRCA (gBRCA) mutation status in patients with HER2-negative early breast cancer in the US community oncology setting: a retrospective observational chart-review study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566540-4000px.png">(PO2-17-07) Risk analysis of the differences in eligibility criteria between monarchE and POTENT clinical trials</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566538-4000px.png">(PO2-17-08) A RETROSPECTIVE ANALYZES OF 4</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566541-4000px.png">(PO2-17-09) Overall survival differences between HER2 Low and other breast cancer subtypes in a reference center in Brazil.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566542-4000px.png">(PO2-17-10) Metaplastic breast cancer: description of 16 cases treated at a reference center and review of the literature.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566554-4000px.png">(PO2-17-11) Management guidelines for epithelial atypia diagnosed in breast screening</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566327-4000px.png">(PO2-17-12) Phase I Trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566602-4000px.png">(PO2-18-01) Assessment of Initial Dosing and Dose Management of Sacituzumab Govitecan-hziy (SG) and How Dosing Practices Impact Duration of Therapy (DOT)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566603-4000px.png">(PO2-18-02) Utilization of Granulocyte Colony-Stimulating Factor (GCSF) in the Management of Patients (pts) on Sacituzumab Govitecan-hziy (SG) and Impact on Duration of Therapy (DOT)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566601-4000px.png">(PO2-18-03) Comparison of Provider Adoption of Antibody-Drug Conjugates Among Breast Cancer Patients (pts) and Impact on Duration of Therapy (DOT)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566418-4000px.png">(PO2-18-04) STX-478 is a potentially best-in-class mutant-selective PI3KÎ± inhibitor that demonstrates robust efficacy in ER+ breast cancer models as monotherapy and in combination with standard of care agents</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566465-4000px.png">(PO2-18-05) Blocking soluble TNF to Improve potency of trastuzumab deruxtecan by increasing internalization and antitumor innate immune response in a resistant HER2-positive breast cancer model</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566508-4000px.png">(PO2-18-06) Targeting fibroblast growth factor receptor (FGFR1) expression through G-quadruplex stabilization inhibits metastatic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566608-4000px.png">(PO2-18-07) Ultrasound â?guided Interstitial Laser therapy for Stage I Breast Cancer: a phase 2 trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566652-4000px.png">(PO2-18-08) Identification of novel genetic&#x2F;therapeutic vulnerabilities in breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566347-4000px.png">(PO2-18-09) A phase 3 randomized open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy in patients with ER+&#x2F;HER2â?early breast cancer and an intermediate or high risk of recurrence (CAMBRIA 1)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566385-4000px.png">(PO2-18-11) Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients (POP-Durva)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566386-4000px.png">(PO2-18-12) Updated Results of a Phase II Study: Neoadjuvant Inetetamab Combined with Pertuzumab</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566396-4000px.png">(PO2-19-01) A Single-Arm Prospective Study of the Neurocognitive Changes Occurring in Breast Cancer Patients on Aromatase Inhibitors. Is There a Difference Between Objective and Perceived Neurocognition?</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566420-4000px.png">(PO2-19-02) NRG-BR009: Phase III Trial Evaluating Addition of Adjuvant Chemotherapy to Ovarian Function Suppression + Endocrine Therapy in Premenopausal Women with pN0-1</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566436-4000px.png">(PO2-19-03) Phase 2 study of response-guided neoadjuvant sacituzumab govitecan in patients with localized breast cancer (NeoSTAR)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566148-4000px.png">(PO2-19-04) Trial in Progress: The REJOIN Trial to Use Exercise and Education to Relieve Joint Pain in Older Breast Cancer Survivors Taking Aromatase Inhibitors</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566447-4000px.png">(PO2-19-05) Randomized Phase II trial evaluating three anti-diarrhoeal prophylaxis strategies in patients with HER2+ &#x2F; HR+ early breast cancer treated with extended adjuvant neratinib (DIANER GEICAM&#x2F;2018-06)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566470-4000px.png">(PO2-19-06) An Open-label</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566481-4000px.png">(PO2-19-07) PROOFS â?Pre-&#x2F;perimenopausal patients with HR+&#x2F;HER2- EBC with intermediate to high clinical and low genomic risk</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566483-4000px.png">(PO2-19-08) INAVO121: Phase III study of inavolisib + fulvestrant vs alpelisib + fulvestrant in patients with hormone receptor-positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566486-4000px.png">(PO2-19-09) INAVO122: a Phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients with PIK3CA-mutated</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566676-4000px.png">(PO2-19-10) CAPItello-292 Phase 3: An open-label</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566505-4000px.png">(PO2-19-11) NOBLE â?Neoadjuvant Olaparib and Durvalumab for patients with BRCA-associated TripLE Negative Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566506-4000px.png">(PO2-19-12) Enhancing skin appearance and quality of life in breast cancer survivors on aromatase inhibitor therapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566507-4000px.png">(PO2-20-01) The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+ Metastatic Breast Cancer (TBCRC 062)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566515-4000px.png">(PO2-20-02) A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+&#x2F; HER2- advanced breast cancer previously treated with a CDK4&#x2F;6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566517-4000px.png">(PO2-20-03) VERITAC-3: A randomized phase 3 study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566522-4000px.png">(PO2-20-04) TACTIVE-U: phase 1b&#x2F;2 umbrella study of vepdegestrant</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566526-4000px.png">(PO2-20-05) Onco-Genome Brazil: Mapping Breast and Prostate Cancer in the Brazilian Public Health System</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566536-4000px.png">(PO2-20-06) Using the Australian Cardio-Oncology Registry to study long-term cancer therapy related cardiac dysfunction in adult oncology patients â?The Chris OâBrien Lifehouse experience</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566412-4000px.png">(PO2-20-07) A case report of a severe cutaneous adverse event in triple negative breast cancer treated with chemoimmunotherapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566948-4000px.png">(PO2-20-08) Metastatic Lung Cancer Masquerading as Metaplastic Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566543-4000px.png">(PO2-20-09) Hiding in plain sight: A heterogeneous response in a patient with metastatic HR+&#x2F;HER2- breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566764-4000px.png">(PO2-20-10) Exceptional long-term disease control on pembrolizumab monotherapy in a patient with TMB-high PMS2-mutated MMR-deficient triple negative breast cancer brain metastasis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566797-4000px.png">(PO2-20-11) Safety and efficacy of KEYNOTE-522 in combination with anti-retroviral therapy in a patient with HIV and triple-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566823-4000px.png">(PO2-20-12) Breast Implant-associated Squamous Cell Carcinoma</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566840-4000px.png">(PO2-21-01) Granular Cell Tumors of the Breast: A Case Series</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566075-4000px.png">(PO2-22-02) Characterization of peripheral T-cell dynamics in the patients with bone metastasis from breast cancer following stereotactic body radiotherapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566165-4000px.png">(PO2-22-03) Reirradiation for locally recurrent breast cancer: a long-term single centre experience</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566240-4000px.png">(PO2-22-04) Median Five-Year Follow-Up Results from the Multi-Institution Trial for the Treatment of Early-Stage Breast Cancer Using Intra-Operative Electronic Brachytherapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566291-4000px.png">(PO2-22-05) A prospective phase I-II study of hypofractionated accelerated breast and nodal intensity modulated radiation therapy delivered in the prone position</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566544-4000px.png">(PO2-22-06) MRI response Assessment of Single Fraction Pre-operative Stereotactic Radiotherapy: Preliminary results</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566150-4000px.png">(PO2-22-07) Predicting Additional Axillary Metastases in Breast Cancer Patients with Positive Targeted Axillary Dissection Lymph Nodes after Neoadjuvant Treatment</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566321-4000px.png">(PO2-22-08) Nipple areolar complex changes after breast-conserving surgical therapy and periareolar mastopexy: a three-dimensional Surface Analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566109-4000px.png">(PO2-22-09) The impact of blood loss and blood pressure management in DIEP flap surgeryâ?a retrospective analysis of 206 patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566399-4000px.png">(PO2-22-10) Surgical outcomes after neoadjuvant chemotherapy with and without immunotherapy in patients with triple negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566411-4000px.png">(PO2-22-11) ‘A sledgehammer to crack a nut’ or ‘the safer option’? Understanding decision making for and against oncoplastic breast conserving surgery as an alternative to mastectomy in women with early breast cancer: The UK ANTHEM study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566410-4000px.png">(PO2-22-12) Patient-reported outcomes 3 and 18 months after prepectoral implant-based breast reconstruction: Results from the UK Pre-BRA multicentre prospective cohort study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566403-4000px.png">(PO2-23-01) Selective cavity margin shaving: effective method to maintain balance between cosmesis and negative margin in breast conserving surgery</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566450-4000px.png">(PO2-23-02) Results of a prospective randomised multicentre study comparing indocyanine green (ICG) fluorescence combined with a standard tracer versus ICG alone for sentinel lymph node biopsy in early breast cancer: The INFLUENCE Trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566524-4000px.png">(PO2-23-03) Potential Candidates for Conservative Axillary Surgery after Neoadjuvant Chemotherapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566570-4000px.png">(PO2-23-05) Practice patterns and outcomes in the ongoing neoadjuvant ATNEC trial: node marking</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566584-4000px.png">(PO2-23-06) Clinical study of stained region lymph node biopsy (SrLNB) in axillary surgery after neoadjuvant systemic therapy in patients with axillary lymph node positive breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566588-4000px.png">(PO2-23-07) Three-dimensional navigated mass spectrometry for intraoperative margin assessment during breast cancer surgery</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567145-4000px.png">(PO2-23-10) Obesity May Modulate the Relationship Between High Mammographic Breast Density and Neoadjuvant Chemoresistance in Early Breast Cancer.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566667-4000px.png">(PO2-23-11) SMAD4 depletion contributes to endocrine therapy resistance by ERBB signaling in HR+HER2- breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566781-4000px.png">(PO2-23-12) Innovative Metastatic Breast Cancer Therapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566478-4000px.png">(PO2-24-01) Kif11 Inhibition Preferentially Kills TP53-mutant Breast Cancer Cells</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566521-4000px.png">(PO2-24-02) Molecular characterization of primary tumors associated with various CTCsâ?subpopulation.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566638-4000px.png">(PO2-24-03) Soluble E-cadherin promotes inflammatory breast cancer tumorigenesis via PDIA4-mediated suppression of ferroptosis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566644-4000px.png">(PO2-24-04) Exploring the role and therapeutic potential of Ubiquitin Specific Peptidase 11 (USP11) in estrogen receptor positive breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566747-4000px.png">(PO2-24-07) Investigation into potential Estrogen Receptor (ER)-mediated regulation of Phosphoserine Aminotransferase (PSAT1)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566766-4000px.png">(PO2-24-09) Prolonged Effects of Hypoxia in Luminal Breast Cancer Cells Promotes an Aggressive Phenotype</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567450-4000px.png">(PO2-24-10) Anti-Tumorigenic Immuno-Microenvironment by AB-329</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566264-4000px.png">(PO2-24-11) Hedgehog signaling influences tumor immunogenicity by the modulation of T cell populations in triple-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566302-4000px.png">(PO2-24-12) Tumor-specific circRNAs elicit anti-tumor immune response via encoding cryptic antigenic peptides</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566349-4000px.png">(PO2-25-01) Tumor Derived Chitinase-3 like 1 Induces Neutrophil Extracellular Traps that Promote T cell Exclusion and Resistance to Immunotherapies in Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566437-4000px.png">(PO2-25-02) The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566446-4000px.png">(PO2-25-03) Deciphering the immune molecular signature associated with pembrolizumab efficacy in the neoadjuvant setting of Triple-Negative Breast Cancer patients: a single-centre experience</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566592-4000px.png">(PO2-25-05) Spatial multiplexing of protein biomarkers for immune cell profiling of the tumor microenvironment with ChipCytometry</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566626-4000px.png">(PO2-25-07) PEGylated Functional Upstream Domain (PEG-FUD): an anti-cancer therapy for breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566089-4000px.png">(PO2-25-08) Role of social isolation and support on all-cause and breast cancer specific mortality among women with breast cancer: The Western New York Exposures and Breast Cancer (WEB) Study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566787-4000px.png">(PO2-25-09) The hidden costs of beauty: An evaluation of breast cancer risk for Black women</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566888-4000px.png">(PO2-25-11) Incidence of Breast Cancer in Louisiana Compared to the United States</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566912-4000px.png">(PO2-25-12) Production of a bespoke muscle resistance exercise (MRE) programme for use in a future clinical trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567016-4000px.png">(PO2-26-01) Prognostic Role of HER2 Expression in Patients with ER-positive&#x2F;HER2-negative Breast Cancer. Results from a Population-Based Cancer Registry Study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567512-4000px.png">(PO2-26-03) Patient decision making and preferences regarding neoadjuvant chemotherapy in Mexican women with early breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567561-4000px.png">(PO2-26-05) Disparities at the Convergence of Race and Ethnicity: Examining Trends and Outcomes in Young Women Diagnosed with Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571042-4000px.png">(PO2-27-01) TFX06</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571052-4000px.png">(PO2-27-02) Re-sensitizing the Refractory Breast Cancer Bone Metastasis to Endocrine Therapies</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571075-4000px.png">(PO2-27-03) Clinical Results of Subjects Remaining in the Phase 3 ARTEST Study Enobosarm Therapy in AR+ER+HER2- Metastatic Breast Cancer with 3 or Greater Prior Lines of Therapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571083-4000px.png">(PO2-27-04) Unravelling the role of FGFR1 in innate immune sensing and endocrine resistance in breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571059-4000px.png">(PO2-27-05) Composite biomarkers for the prediction of progression-free survival with CDK4&#x2F;6 inhibitors in metastatic HR+&#x2F;HER2- breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571017-4000px.png">(PO2-27-06) ANXA9 facilitates the exocrine secretion of S100A4 and promotes pleural metastasis in breast cancer.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571040-4000px.png">(PO2-27-07) The Role of HCMV Infection in Facilitating Brain Metastasis through the Creation of a Suppressive Tumor Microenvironment in Breast Cancer Patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571149-4000px.png">(PO2-27-08) Discovery of glucocorticoid receptor-induced EMT and integrin gene expression and increased cell motility in invasive lobular breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571018-4000px.png">(PO2-27-11) Antitumor efficacy and safety of sacibertinib (Hemay022) in combination with endocrine therapy in patients with ER+ and HER2+ metastatic breast cancer: A phase Ib study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571058-4000px.png">(PO2-27-12) Genomic determinants of benefit to nivolumab (NIVO) plus low dose ipilimumab (IPI) among patients (pts) with hypermutated HER2-negative metastatic breast cancer (MBC): results of NIMBUS trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2576726-4000px.png">(PO2-28-01) Deleting caveolin-1 in epithelial cells increases doxorubicin sensitivity in advance stage of breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571039-4000px.png">(PO2-28-02) ROR1 regulates CREB3L1 via a novel signaling pathway in triple negative breast cancer.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571129-4000px.png">(PO2-28-03) E-Cigarette Aerosol Exposure: Unraveling the Nexus of Autophagy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571147-4000px.png">(PO2-28-04) Pregnancy-associated relapse of triple-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571053-4000px.png">(PO2-28-06) An on-line deep learning decision support tool</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571056-4000px.png">(PO2-28-07) Artificial Intelligence-based Computer-aided Diagnosis for Mammography: Predicting Occult Invasive Cancer in Women with Biopsy-proven Ductal Carcinoma in Situ</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571073-4000px.png">(PO2-28-08) A spatial transcriptomic study of a triple-negative breast cancer (TNBC) patient-derived xenograft (PDX) model of residual disease refractory to conventional chemotherapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571087-4000px.png">(PO2-28-09) Long-term Breast Cancer Risk Prediction in Black Women: External Validation of a Mammography-driven AI Model</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571049-4000px.png">(PO2-28-10) Analysis of whole breast ultrasound image sequence reading time with a new FDA approved automated whole breast ultrasound tomography system for supplemental screening in women with dense breasts</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571061-4000px.png">(PO2-28-11) How to improve margins in breast cancer surgery: a</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571091-4000px.png">(PO2-28-12) Rapid diagnosis of breast biopsies with open-top light-sheet microscopy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571010-4000px.png">(PO2-29-01) POSITIVE PREDICTIVE VALUE FOR THE MALIGNANCY OF MAMMOGRAPHIC ABNORMALITIS IN A ONE-STOP CLINIC MODEL FOR BREAST CANCER IN COLOMBI</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571024-4000px.png">(PO2-29-02) Towards Precision Medicine in Breast Imaging: A Novel Open Mammography Database with Tailor-Made 3D Image Retrieval for Artificial Intelligence and Teaching</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571034-4000px.png">(PO2-29-03) Factors Affecting the Mammography Sensitivity and the Quality of the Breast Cancer Screening Program in the State of SÃ£o Paulo</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571067-4000px.png">(PO2-29-04) An AI-based safeguard process to reduce aggressive missed cancers in dense breasts at screening mammography</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566662-4000px.png">(PO3-01-01) Dysregulation of Phenylalanine-tyrosine Metabolic Signaling Pathway and Neoadjuvant Response in HER2-positive Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566768-4000px.png">(PO3-01-02) Real world outcomes of neoadjuvant therapy with Trastuzumab and Pertuzumab associated with carboplatin and docetaxel (TCHP) in HER2+ early breast cancer patients unfit for anthracyclines: a retrospective cohort comparative study.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566969-4000px.png">(PO3-01-04) Neoadjuvant compared to adjuvant chemotherapy combined with trastuzumab in patients with HER2-positive breast cancer: a register-based cohort study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567212-4000px.png">(PO3-01-05) Enhancing HER2 Evaluation: Correlation between APIS Breast Cancer Subtyping Kit and IHC&#x2F;ISH for Accurate HER2 Quantification</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566576-4000px.png">(PO3-01-08) Interaction of Prior Chemotherapy and Addition of Ovarian Function Suppression on Menopausal Symptoms in Tamoxifen-Treated Breast Cancer Patient: A prospective</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566620-4000px.png">(PO3-01-09) Results of a prospective observational study evaluating the impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR+&#x2F;HER2- breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566627-4000px.png">(PO3-01-10) Changes in Patient-Reported Outcomes with 3 Months of Pre-operative Endocrine Therapy in the POWER Trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566631-4000px.png">(PO3-01-11) Clinical Significance of HER2-low Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566659-4000px.png">(PO3-01-12) Clinicopathologic Factors affecting response in patients with Estrogen receptor-positive and Human Epidermal Growth Factor Receptor-negative breast cancer receiving neoadjuvant chemotherapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566683-4000px.png">(PO3-01-13) A study of the impact of the implementation of the Oncotype Dx 21-gene breast-cancer assay during the SARS-CoV-2 pandemic for 1-3 node positive early breast cancer: The Clatterbridge Cancer Centre Experience</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566690-4000px.png">(PO3-01-14) Impact of detection mode</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566748-4000px.png">(PO3-02-01) Educational Opportunities to Improve Community Healthcare Professionalsâ?Management of High-Risk HR-Positive&#x2F;HER2-Negative Early Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566769-4000px.png">(PO3-02-02) A prospective</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566782-4000px.png">(PO3-02-03) Ketogenic diet and letrozole to inhibit PI3K signaling in ER+ breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566790-4000px.png">(PO3-02-04) Comparison of OncotypeDX Recurrence Scores (RS) and MammaPrint (MP) scores</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566854-4000px.png">(PO3-02-05) Racial and Ethnic Differences in Clinical Outcomes among North American Patients with Hormone Receptor-Positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566865-4000px.png">(PO3-02-06) Predictive Factors for adjuvant radiation use in patients &gt;70 years with pT1N0 HR+ breast cancers</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566661-4000px.png">(PO3-02-07) HER2-low status in inflammatory breast cancer (IBC) is associated with hormone receptors positivity but not with pathological response to neoadjuvant chemotherapy or overall survival</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566665-4000px.png">(PO3-02-08) Risk factors and a new predictive nomogram for predicting the Non-sentinel Lymph Node Metastasis in 708 early-stage Breast Cancer Patients with Positive Sentinel Nodes in China</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566717-4000px.png">(PO3-02-09) Breast cancer in women under the age of 40 years.A south Wales UK reflection on incidence</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566793-4000px.png">(PO3-02-11) Impact of Tumor Volume on Oncologic Outcomes in Patients with T1 Breast Cancer: A Retrospective Analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566795-4000px.png">(PO3-02-12) Dalpiciclib combination with letrozole as neoadjuvant therapy for HR-positive HER2-negative breast cancer: a single-arm</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566798-4000px.png">(PO3-02-13) Breast Cancer in Very Young Adult Women At or Under the Age of 35 Years: Characteristics and Outcomes</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566803-4000px.png">(PO3-02-14) The Safety of Breast Reconstruction: The Impact of Breast Reconstruction Surgery on Postoperative Adjuvant Therapy for Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566831-4000px.png">(PO3-03-01) Impact of Environmental Temperature on Clinical Outcomes and Tumor Microenvironment of Early-Stage Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566875-4000px.png">(PO3-03-02) Effect of Surgery on Breast Cancer-Specific Mortality in Elderly Patients with Hormone Receptor-Positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566922-4000px.png">(PO3-03-03) Prospective non-randomized study to compare accuracy of clinical examination under anesthesia</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566928-4000px.png">(PO3-03-04) Metaplastic breast cancer: a single center retrospective study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566838-4000px.png">(PO3-03-05) Clinical outcomes in early-stage TNBC according to HER2-low status</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566886-4000px.png">(PO3-03-07) Patterns of Chemotherapy Utilization among Elderly Patients with Early-Stage Triple-Negative Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566889-4000px.png">(PO3-03-08) Use of adjuvant Capecitabine after neoadjuvant chemotherapy: A Cohort Study among Elderly Patients with Early-Stage Triple-Negative Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566897-4000px.png">(PO3-03-09) Clinical Significance of Grade in Triple Negative Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566934-4000px.png">(PO3-03-10) Race and neoadjuvant treatment of triple negative breast cancer (TNBC) in the US community oncology setting</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566958-4000px.png">(PO3-03-11) Receptor discordance after neoadjuvant chemotherapy with pembrolizumab in early-stage triple-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566956-4000px.png">(PO3-03-12) Factors associated with response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566732-4000px.png">(PO3-04-01) Population Pharmacokinetics of trastuzumab deruxtecan (T-DXd) in HER2-positive breast cancer subjects: analyses across 12 Phase 1-3 studies</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566754-4000px.png">(PO3-04-02) Exposure-efficacy and safety analysis of trastuzumab deruxtecan (T-DXd) in patients with advanced&#x2F;metastatic HER2+ breast cancer (BC): Analyses from Phase 3 Studies DESTINY-Breast02 (DB-02) and DESTINY-Breast03 (DB-03)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566759-4000px.png">(PO3-04-03) Drug Holidays in Patients with HER-2 Positive Metastatic Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566791-4000px.png">(PO3-04-04) Long term survival of metastatic HER2 positive breast cancer patients with no radiographic evidence of disease (NED) on HER2 antibody therapy.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566903-4000px.png">(PO3-04-05) Efficacy and safety of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive or HER2-low expressing</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566914-4000px.png">(PO3-04-06) A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567068-4000px.png">(PO3-04-07) Characterization of response to first-line chemotherapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566401-4000px.png">(PO3-04-10) Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+&#x2F;HER2- ABC in the first- or second-line setting: A multicenter observational study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566449-4000px.png">(PO3-04-11) Unmet clinical need in patients with pre-treated hormone receptor-positive&#x2F;HER2-negative (HR+&#x2F;HER2â? metastatic breast cancer in routine care: a targeted literature review</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566462-4000px.png">(PO3-04-12) SUMIT-BC: Phase 2 randomized study of fulvestrant with or without the cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4&#x2F;6i</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566463-4000px.png">(PO3-04-13) SUMIT-ELA: Phase 1b&#x2F;2 combination of cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib and selective estrogen receptor degrader (SERD) elacestrant in advanced hormone receptor positive (HR+) breast cancer after CDK4&#x2F;6i</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566497-4000px.png">(PO3-05-01) Locoregional Management Based on Mode of Progression for HR+&#x2F;HER2- metastatic breast cancer Treated with Combined CDK4&#x2F;6 inhibitor with Aromatase inhibitor.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566501-4000px.png">(PO3-05-02) Impact of hormone receptor expression level in HR+&#x2F;HER2- metastatic breast cancer in the large French ESME cohort.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566514-4000px.png">(PO3-05-03) Real-World Data on First-line Treatment of Hormone Receptor-positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566572-4000px.png">(PO3-05-04) Characteristics and clinical outcome of patients with HR positive HER2 low metastatic breast cancer treated with CDK 4&#x2F;6 inhibitors</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566573-4000px.png">(PO3-05-05) The effect of histological breast cancer subtype on progression free survival in patients with CDK4&#x2F;6 inhibitors</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566583-4000px.png">(PO3-05-06) Targeting PAM50 HER2-Enriched intrinsic subtype with enzalutamide in hormone receptor-positive&#x2F;HER2-negative (HR+&#x2F;HER2-) advanced breast cancer: results of the SOLTI-1502 ARIANNA trial.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566587-4000px.png">(PO3-05-07) SOLTI-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive&#x2F;HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566589-4000px.png">(PO3-05-08) Updated results from VERITAC evaluating vepdegestrant</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566624-4000px.png">(PO3-05-09) The impact of body mass index on CDK4&#x2F;6 inhibitor treatment survival outcomes in metastatic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566688-4000px.png">(PO3-05-10) Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multi-center</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566708-4000px.png">(PO3-05-11) Enhancing the interpretation of real-world quality of life (QoL) in patients (pts) with hormone receptor positive human epidermal growth factor 2 negative (HR+&#x2F;HER2â? advanced breast cancer (ABC) enrolled in the POLARIS trial.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566712-4000px.png">(PO3-05-12) Randomized Phase 2 of Bria-IMT</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566742-4000px.png">(PO3-05-13) A Multi-Institutional Review of Contralateral Axillary Metastases: Time for Reclassification as Local-Regional Event?</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566765-4000px.png">(PO3-05-14) Practice patterns for sequential use of antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer: results from a physician survey</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566828-4000px.png">(PO3-06-01) Factors associated with first- and second- line attrition among metastatic breast cancer patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566852-4000px.png">(PO3-06-02) Ten years axillary recurrence and survival after omission of axillary lymph node dissection in breast cancer patients with micrometastases or isolated tumor cells in the sentinel node: A Danish national register study.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566883-4000px.png">(PO3-06-03) Overall Survival and Disease Interval Among Breast Cancer Subtypes in Patients with Brain Metastasis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566997-4000px.png">(PO3-06-04) Clinical Features and Survival Outcomes of Oligometastatic Breast Cancer Patients: The Mayo Clinic Experience</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566999-4000px.png">(PO3-06-05) Association of tumor-derived extracellular vesicles with circulating tumor DNA alterations in metastatic breast cancer patients: exploring differences in inflammatory breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567193-4000px.png">(PO3-06-07) Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): preliminary results of a single-arm</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566762-4000px.png">(PO3-06-09) A phase II study of nivolumab plus ipilimumab and androgen receptor antagonist bicalutamide to stimulate thymic T cell generation in HER2-negative metastatic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566805-4000px.png">(PO3-06-10) Real World Outcomes with Sacituzumab Govitecan in Metastatic Triple Negative Breast Cancer Patients: A Multi-Institution Study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566811-4000px.png">(PO3-06-11) Undated analyses from a Phase Ib open-label study of Pucotenlimab (HX008) in combination with gemcitabine and cisplatin as first-line treatment of metastatic triple-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566818-4000px.png">(PO3-06-12) Targeting Fatty Acid Synthase in Brain Metastatic Triple-negative Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566885-4000px.png">(PO3-06-13) A novel stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor targeting microtubules (60c) is effective against taxane-resistant</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566920-4000px.png">(PO3-06-14) Phase I&#x2F;II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566645-4000px.png">(PO3-07-01) Multiscale Computational Analysis of Patient-Matched Multi-Modal Imaging of Breast Tissue Microenvironment</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566673-4000px.png">(PO3-07-02) Radiomics Models for B-mode Breast Ultrasound and Strain Elastography to improve Breast Cancer Diagnosis (INSPiRED 005): An International</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566680-4000px.png">(PO3-07-03) Development &amp; Validation of an AI-supported Workflow for Clinical Scoring of HER2</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566753-4000px.png">(PO3-07-04) Prediction of PAM50 molecular subtypes from H&amp;E-stained breast cancer specimens using tumor microenvironment features and additive multiple instance learning models</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566757-4000px.png">(PO3-07-05) Multi-site validation of a deep learning solution for ER&#x2F;PR profiling of breast cancer from H&amp;E-stained pathology slides</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566472-4000px.png">(PO3-07-06) Correlation between residual microcalcification and in-breast pathologic response in relation to MRI response and the subtypes after neoadjuvant chemotherapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566350-4000px.png">(PO3-07-07) Predictive Modeling for Identifying Breast Cancer Patients Eligible for Axillary Lymph Node Dissection Exemption Following Neoadjuvant Therapy: A Longitudinal MRI-based Radiomics and Deep Learning Features Analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566535-4000px.png">(PO3-07-08) Breast density estimation with a microwave-frequency imaging system</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566550-4000px.png">(PO3-07-09) B3 breast lesions in Asian Centers: malignant upgrade rates and risk factors</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566641-4000px.png">(PO3-07-10) Advanced CD8 ImmunoPET imaging predicts radiation response in primary TNBC</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566752-4000px.png">(PO3-07-11) Concordance between abbreviated and complete magnetic resonance protocols for screening woman at moderate and high risk for breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566792-4000px.png">(PO3-07-12) Effect of neoadjuvant chemotherapy on peritumoral edema in early stage breast cancer and its prognostic value</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566733-4000px.png">(PO3-08-01) Decision curve analysis to compare breast cancer risk predictions for a polygenic integrated clinical risk model with those of a gold standard</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566756-4000px.png">(PO3-08-03) Comparing prognosis for BRCA1</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566758-4000px.png">(PO3-08-04) Prevalence of BRCA1&#x2F;2 mutations in an underrepresented population of women with breast cancer: Observations from the City of Hope INSPIRE study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567188-4000px.png">(PO3-08-05) Prognostic value of multigene test to the patients with Hormone receptor-positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566853-4000px.png">(PO3-08-06) Challenges in Implementing Genetic Counseling and Genetic Testing for Breast Cancer: Insights from the First 1000 Families Assessed in a Public University Hospital in Argentina</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566858-4000px.png">(PO3-08-07) Licochalcone A as a risk reducing agent against luminal and non-luminal breast cancers.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566859-4000px.png">(PO3-08-08) Basal-Luminal (BL) Cells in Histologically Normal and Malignant Breast Tissue from BRCA1 and BRCA2 Carriers</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2571051-4000px.png">(PO3-08-09) Unique molecular signatures of germline mutations in low expression of human epidermal growth factor receptor 2 (HER2) breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566895-4000px.png">(PO3-08-10) Somatic mutations of a multigene panel in Chinese HER2-positive patients undergoing neoadjuvant therapy and impact on prognosis based on TP53 statusï¼a single-institution retrospective cohort</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566925-4000px.png">(PO3-08-11) Association between Histologic Variants and the Results of Multigene Testing in Patients with Hormone Receptor-positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567010-4000px.png">(PO3-09-01) Integrating pathomic and radiomic images to classify risk of subsequent events among women with DCIS</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567019-4000px.png">(PO3-09-02) Identifying risk factors for trastuzumab-induced cardiotoxicity among multi-ethnic women with HER2-positive early-stage breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567036-4000px.png">(PO3-09-03) Dysbiosis of gut microbiota in patients with breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567074-4000px.png">(PO3-09-04) Identification of germline pathogenic variants to guide systemic therapy: Prevalence and spectrum of PVs among Mexican patients with metastatic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566775-4000px.png">(PO3-09-06) Role of Obesity-Related Biomarkers on Mortality Among Black Breast Cancer Survivors in the Womenâs Circle of Health Followup Study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566777-4000px.png">(PO3-09-07) When We Tri(al): Reaching</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566778-4000px.png">(PO3-09-08) Using Social Determinants of Health to Improve Surgical Delays for Breast Cancer Patients at Rush University Cancer Center</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566783-4000px.png">(PO3-09-09) Interventions to improve adherence to oral endocrine therapy for prevention or treatment of breast cancer in African American women of low socioeconomic status</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566802-4000px.png">(PO3-09-10) Minority participation in breast cancer therapeutic trials at an NCI-CCC affiliated safety-net system: Advancing equity in clinical research.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566820-4000px.png">(PO3-09-11) Age Group Analysis of Breast Cancer Patterns in Brazil: Findings from Population-Based Registries</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566308-4000px.png">(PO3-09-12) Exploring Gender-Specific Patterns of Breast Cancer in Brazil: A Comparative Epidemiological Study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566847-4000px.png">(PO3-10-01) How The Financial Toxicity of Metastatic Breast Cancer Affects Single Mothers with Young Children: Where Disparities Lie and Outcomes For Quality of Life</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566856-4000px.png">(PO3-10-02) Cardiovascular Risk Factors and Outcomes in Native Americans who have Received Chemotherapy and&#x2F;or Radiation: A Retrospective Single-center Study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566961-4000px.png">(PO3-10-03) Nationwide Impact of Neighborhood Poverty Hotspots on Breast Cancer Mortality</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566891-4000px.png">(PO3-10-06) Parenting While Living with Cancer - Providing Better Outcomes for Families During the Cancer Journey</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566905-4000px.png">(PO3-10-07) Leveraging AI to identify factors influencing access to care and their association with overall survival- a multiracial Breast Cancer cohort.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566918-4000px.png">(PO3-10-09) The allocation of US $2.6 billion in global funding for breast cancer research between 2016 â?2020: are we investing wisely for breast cancer patients?</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566932-4000px.png">(PO3-10-10) Are we adequately integrating patient reported outcomes in breast cancer clinical trials?</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566940-4000px.png">(PO3-10-11) Mujeres Avanzando a la Sobrevida (MAS: women going forward in survival): Breast Cancer Characteristics and Delays in Care in Honduras</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567143-4000px.png">(PO3-11-01) Single centre experience of the adoption of self-administered HER2-directed therapy in patients with breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567215-4000px.png">(PO3-11-02) Characterizing Breast Cancer Care Fragmentation Among Young Black Women Diagnosed with Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2576713-4000px.png">(PO3-11-03) A Randomized Controlled Trial to Assess the Benefit of Art &amp; Music Therapy on Quality of Life in Patient with Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566877-4000px.png">(PO3-11-05) Sexual dysfunction among Brazilian women with early breast cancer on adjuvant endocrine therapy (ET)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566879-4000px.png">(PO3-11-06) Return to work in Brazilian women on adjuvant endocrine therapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567160-4000px.png">(PO3-11-07) Dose-response association between post-diagnosis exercise and clinical outcomes among survivors of breast cancer (BC)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566884-4000px.png">(PO3-11-08) High Risk of Metabolic Dysfunction in Non-Obese Breast Cancer Survivors</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566894-4000px.png">(PO3-11-09) Cross-cultural adaptation and psychometric validation of lymphedema patient-reported outcome measurements in Chinese breast cancer patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566924-4000px.png">(PO3-11-10) Second primary non-breast cancers in young breast cancer survivors</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566951-4000px.png">(PO3-11-11) Reproductive concerns of Japanese young women with breast cancer: a longitudinal study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566954-4000px.png">(PO3-11-12) A Pragmatic Randomized Trial Comparing Morning versus Evening Dosing of Endocrine Therapy for Early Breast Cancer: Final Results (REaCT-CHRONO Study).</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566955-4000px.png">(PO3-12-01) Breastfeeding After Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2576714-4000px.png">(PO3-12-04) Pulmonary Complication related to Trastuzumab Deruxtecan. A pharmacovigilance study from 2022-2023 FAERS Database</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566774-4000px.png">(PO3-12-05) Patient (pt)-provider communication challenges about side effects&#x2F;toxicities from metastatic breast cancer (mBC) treatments</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566817-4000px.png">(PO3-12-06) The pilot study for a mobile-based monitoring solution to manage menopausal symptoms of premenopausal breast cancer patients with endocrine therapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566824-4000px.png">(PO3-12-07) Utility of Volumetric Measurement for Clinical Diagnosis of Breast Cancer-Related Lymphedema</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566873-4000px.png">(PO3-12-08) Hypersensitivity reactions to paclitaxel and carboplatin in breast cancer: safety and effectiveness of desensitization.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566916-4000px.png">(PO3-12-09) De-Escalating Extent of Sentinel Lymph Node Biopsy in Patients with Ductal Carcinoma in Situ Undergoing Mastectomy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566957-4000px.png">(PO3-12-10) Cryotherapy to Prevent Taxane-Induced Sensory Neuropathy of the Hands and Feet</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566974-4000px.png">(PO3-12-11) A phase-3 randomized controlled study to evaluate the role of hydroxyprogesterone in prevention of chemotherapy induced neurotoxicity in women with breast cancer.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566980-4000px.png">(PO3-12-12) Axial Neuropathy in Two Breast Cancer Patients receiving Fam-trastuzumab deruxtecan: A Case Report</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567009-4000px.png">(PO3-13-01) ONTARGET: Phase 3 randomized</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566779-4000px.png">(PO3-13-02) Genomic and intrinsic subtype correlates of serum thymidine kinase activity in patients with metastatic breast cancer treated with palbociclib and fulvestrant in the PYTHIA trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566788-4000px.png">(PO3-13-03) RNAScope: a practical approach and promising alternative to immunohistochemistry to quantify HER2 expression in breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566789-4000px.png">(PO3-13-04) The role of sphingolipids in cancer progression and its microenvironment in breast cancer patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566796-4000px.png">(PO3-13-05) PD-L1 and PD-L2 Protein Expression is Frequently Discordant in Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566806-4000px.png">(PO3-13-06) TILs are an independent prognostic factor in early-stage TNBC patients achieving pathologic complete response after neoadjuvant chemotherapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566809-4000px.png">(PO3-13-07) MUC1-C INTEGRATES CHRONIC ACTIVATION OF INTERFERON PATHWAYS WITH CHROMATIN REMODELING IN TREATMENT RESISTANCE OF TRIPLE-NEGATIVE BREAST CANCER</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566816-4000px.png">(PO3-13-08) D17104: Aryl Hydrocarbon Receptor Signaling and Other Biomarkers of Fat Metabolism in Human Mammary Adipose Tissue from Women with Malignant Breast Disease</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566835-4000px.png">(PO3-13-09) Personalized ctDNA testing for detection of molecular residual disease in patients with localized HR+ breast cancer: temporal dynamics and impact on clinical outcomes</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566841-4000px.png">(PO3-13-10) Proteogenomic characterization of primary invasive breast tumors from young women compared to matched tumors from older women</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566849-4000px.png">(PO3-13-11) Quantitative Multiplex Immunofluorescence Assay for TROP2 and HER2 Expression in Breast Cancer: Towards Guiding Patient Selection for Antibody Drug Conjugate Therapies</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566863-4000px.png">(PO3-13-12) ER-positive&#x2F;HER2-negative breast cancer in Adolescent &amp; Young Adult (AYA) age group has a specific biological feature and worse outcome compared to other generations</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566874-4000px.png">(PO3-14-01) Heterogeneity of tumor immune microenvironment to predict everolimus efficacy in premenopausal women with hormone receptor-positive&#x2F;human epidermal growth factor receptor 2-negative adavanced breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566906-4000px.png">(PO3-14-04) Prognostic value of systemic inflammatory markers in neoadjuvant chemotherapy for breast triple negative cancer with pembrolizumab: development of a nomogram</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566933-4000px.png">(PO3-14-05) Integration of metabolomics and transcriptomics to Reveal Potential Biomarkers Associated with Treatment Response of Neoadjuvant Therapy in HER2+ Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566939-4000px.png">(PO3-14-06) Immunologic features and association with prognosis in hormone receptor-positive&#x2F;HER2-negative (HR+&#x2F;HER2-) metastatic breast cancer (MBC) treated with chemotherapy (CT) or CDK4&#x2F;6-inhibitors (CDK4&#x2F;6i) + endocrine therapy (ET)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566941-4000px.png">(PO3-14-07) Characterizing Immune Infiltration in Metastatic Hormone Receptor-Positive&#x2F;HER2-Negative Breast Cancer: A Comprehensive Translational Analysis from four SOLTI Clinical Trials</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566946-4000px.png">(PO3-14-08) Metaplastic Breast Cancer: Whole Genome Sequencing Analysis and Emerging Therapeutic Targets</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566973-4000px.png">(PO3-14-10) A single-center prospective cohort study to evaluate circulating tumor cells as a monitoring tool in women with breast cancer treated with neoadjuvant chemotherapy: final results of baseline data</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566976-4000px.png">(PO3-14-11) Association between BRCA alterations detected by circulating tumor DNA and germline mutations in breast cancer patients: a retrospective mono-institutional analysis.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566981-4000px.png">(PO3-14-12) SIRT3 as a new potential predictive biomarker for response to CDK4&#x2F;6 inhibition in ER+&#x2F;HER2- metastatic breast cancer patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566899-4000px.png">(PO3-15-01) Overexpression of N-glycosylation related gene OST4 promotes chemotherapy resistance in triple-negative breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566993-4000px.png">(PO3-15-02) TP53 GENE POLYMORPHISM AT CODON 72 AS A RESPONSE PREDICTOR FOR NEOADJUVANT CHEMOTHERAPY</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567002-4000px.png">(PO3-15-03) Abemaciclib is effective in palbociclib resistant estrogen receptor positive breast cancers</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567004-4000px.png">(PO3-15-04) Oncotype DX Recurrence Score as an Informative Tool to Optimize Neoadjuvant Therapy in HR-positive</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566382-4000px.png">(PO3-15-06) Identification of a Novel Five Ferroptosis-Related Gene Signature as a Promising Prognostic Model for Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567022-4000px.png">(PO3-15-08) Validation for prognostic staging based AJCC 8th edition with nuclear grade in Japanese breast cancer patients: A multicenter retrospective study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567023-4000px.png">(PO3-15-09) LobSig4 is a superior and readily implementable ILC-focussed prognostic biomarker set.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567024-4000px.png">(PO3-15-10) Enhanced Cancer Cell Proliferation and Aggressive Phenotype Counterbalance in Breast Cancer with High BRCA1 Gene Expression</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567027-4000px.png">(PO3-15-11) Soluble sFas</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567039-4000px.png">(PO3-15-12) Expression and co-expression patterns of TROP2 and HER2 in breast cancer: implications for bispecific antibody-drug conjugate therapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567123-4000px.png">(PO3-16-02) Trastuzumab and taxane chemotherapy in the first-line in MBC patients with a HER2-negative primary tumor and HER2-positive circulating tumor cells: a phase II trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567131-4000px.png">(PO3-16-03) Investigating HER2DX genomic assay concordance within HER2-positive breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567137-4000px.png">(PO3-16-04) Distribution of intrinsic subtypes in endocrine-resistant and endocrine-sensitive breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2573019-4000px.png">(PO3-16-05) Mitochondrial DNA mutation detection in tumors and circulating extracellular vesicles of triple negative breast cancer patients for biomarker development</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566632-4000px.png">(PO3-16-06) Perceptions and experiences of patients and healthcare providers on genetic testing and treatment of early breast cancer: qualitative findings</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566634-4000px.png">(PO3-16-07) Strategies to Enact for Equitable and Unbiased Care of Black</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566635-4000px.png">(PO3-16-08) Real-World Treatment Patterns in Elderly Patients with HER2-Negative Early Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566655-4000px.png">(PO3-16-09) Real-World Experience with Trastuzumab Deruxtecan at a Diverse NCI Comprehensive Cancer Center</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566666-4000px.png">(PO3-16-10) Real-world outcomes with first-line ribociclib + endocrine therapy in patients with metastatic HR+</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566689-4000px.png">(PO3-16-11) Attrition rates from first- to third-line therapy in HER2+ metastatic breast cancer in Europe</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566711-4000px.png">(PO3-16-12) European real-world experience of patients with HER2+ advanced&#x2F;metastatic breast cancer accessing trastuzumab deruxtecan through a named patient program: first interim analysis of EUROPA T-DXd</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567141-4000px.png">(PO3-17-02) Analysis of clinical benefit in the real world of HER2-positive metastatic breast cancer following the development of anti-HER2 therapeutics over the past 20 years</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566821-4000px.png">(PO3-17-03) Impalpable breast lesion localisation device satisfaction in UK surgeons and radiologists: results of the iBRA-NET national practice questionnaire</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566825-4000px.png">(PO3-17-04) HER2-directed biosimilar Ogivri in the treatment of breast cancer: real world reporting of symptoms and wellbeing using electronic patient reported outcome (ePRO)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566834-4000px.png">(PO3-17-05) Clinical Characteristics and Outcomes of Patients Receiving Adjuvant Paclitaxel and Trastuzumab (APT regimen) for HER2-Positive Early-Stage Breast Cancer in Brazil: A Real-World Evidence</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566870-4000px.png">(PO3-17-07) Real-world experience with trastuzumab deruxtecan in patients with breast cancer: 6 month-interim analysis of an all-patient postmarketing surveillance in Japan</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566872-4000px.png">(PO3-17-08) SAFETY AND TOLERABILITY OF SUBCUTANEOUS TRASTUZUMAB AS A TREATMENT IN PATIENTS WITH EARLY HER 2 POSITIVE BREAST CANCER : EXPERIENCE OF A CANCER CENTER IN PERU</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566901-4000px.png">(PO3-17-09) Outcome after the introduction of personalized treatment for axilla in patients with clinically node-negative early breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566944-4000px.png">(PO3-17-10) Real-World evidence for Pembrolizumab-based neoadjuvant chemotherapy in early-stage triple negative breast cancer: a single institution experience.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566968-4000px.png">(PO3-17-11) The Utility of Oncotype DX in Grade 1 Hormone Receptor-Positive Early Breast Cancer: Insights from a Multicentric Real-World Data Study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566987-4000px.png">(PO3-17-12) Safety and efficacy of Atezolizumab in combination with nab-Paclitaxel in patients with PD-L1 positive metastatic or locally advanced triple-negative breast cancer: A pan-UK cancer centre experience.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567005-4000px.png">(PO3-18-01) Cirrhosis is associated with worse post-operative survival among patients with breast cancer: a population-based study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567020-4000px.png">(PO3-18-02) RISK FACTORS FOR DEATH IN ELDERLY PATIENTS WITH BREAST CANCER TREATED IN AN ONCOLOGY REFERENCE HOSPITAL IN THE CITY OF RECIFE</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566663-4000px.png">(PO3-18-03) Preoperative single-dose camrelizumab and&#x2F;or microwave ablation in women with early-stage breast cancer: A randomized window-of-opportunity trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566695-4000px.png">(PO3-18-04) MBRC-101: a novel antibody-drug conjugate (ADC) targeting the membrane-associated tyrosine kinase receptor EphA5 in breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566746-4000px.png">(PO3-18-05) Pharmacokinetics (PK) of lasofoxifene (LAS) monotherapy and combined with abemaciclib (Abema)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566784-4000px.png">(PO3-18-06) First-in-human phase 1A study of RGT-419B</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566842-4000px.png">(PO3-18-07) Therapeutic Potential of Combining Eltanexor with Tamoxifen to Treat Primary and Metastatic Estrogen Receptor Positive (ER+) Breast Cancers</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566844-4000px.png">(PO3-18-08) Rational therapeutic combination of Bromodomain and Extra-Terminal domain (BET) inhibitor and Fibroblast Growth Factor Receptor (FGFR) inhibitor for treatment of invasive lobular carcinoma</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566718-4000px.png">(PO3-18-09) OPERA-01: A randomized</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566581-4000px.png">(PO3-18-11) A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib&#x2F;placebo in patients with residual HER2-positive invasive breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566591-4000px.png">(PO3-18-12) Results from a first-in-human study of DAN-222</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566604-4000px.png">(PO3-19-01) A Randomized Controlled Trial of Metastasis-directed Therapy for Oligometastases in Breast Cancer (OLIGAMI trial; JCOG2110)</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566606-4000px.png">(PO3-19-02) White Button Mushroom and Biomarkers of Immune Cell and Inflammatory Responses in Obese Postmenopausal Women at High Risk of Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566616-4000px.png">(PO3-19-03) Addressing USPSTF 2023 Identified Key Gaps in Knowledge in Breast Cancer Screening through TMIST (ECOG-ACRIN EA1151) or its Ancillary Studies</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566628-4000px.png">(PO3-19-04) The CROWN STUDY: A multicenter prospective cohort study of cardiovascular outcomes in premenopausal women with hormone receptor positive breast cancer treated with ovarian suppression and an aromatase inhibitor</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566633-4000px.png">(PO3-19-05) Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566640-4000px.png">(PO3-19-06) MRD Assay evaluates Recurrence and response via a tumor Informed Assessment: MARIA-Breast Observational Trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566658-4000px.png">(PO3-19-07) AC699-001</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566664-4000px.png">(PO3-19-08) A phase 2 randomized pre-operative</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566674-4000px.png">(PO3-19-09) SERENA-1: Results from a Phase 1 study (Parts I&#x2F;J) testing the next-generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) in combination with capivasertib in women with ER+</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566500-4000px.png">(PO3-19-10) Phase 1b study of EZH1&#x2F;2 inhibitor valemetostat in combination with trastuzumab deruxtecan in subjects with HER2 low&#x2F;ultra-low&#x2F;null metastatic breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566684-4000px.png">(PO3-19-11) CINDERELLA Clinical Trial (NCT05196269): using artificial intelligence-driven healthcare to enhance breast cancer locoregional treatment decisions</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566693-4000px.png">(PO3-19-12) Evaluating the impact of ePRO-based follow-up system (Pink Ribbon Diary) on quality of life and treatment adherence in patients with breast cancer receiving CDK4&#x2F;6 inhibitors: a single center</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566702-4000px.png">(PO3-20-01) ASTEFANIA: a Phase III study of ado-trastuzumab emtansine plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567078-4000px.png">(PO3-20-02) Olaparib front line therapy with endocrine therapy in locally advanced unresectable or in metastatic breast cancer: OFELIA TRIAL</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566563-4000px.png">(PO3-20-03) First-in-human global study of RLY-2608</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566719-4000px.png">(PO3-20-04) A first-in-human study of the highly selective PI3KÎ± inhibitor RLY-5836 in patients with advanced breast cancer and other solid tumors</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566720-4000px.png">(PO3-20-05) Phase II Study of Genomically Guided Radiation Dose Personalization in the Management of Triple Negative Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566728-4000px.png">(PO3-20-06) TRUDI: A phase II study of neoadjuvant TRastuzumab derUxtecan and Durvalumab for stage III HER2-expressing Inflammatory breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566929-4000px.png">(PO3-20-07) Five years and counting: A case of a 47-year-old female with De Novo Metastatic HER2 positive disease on multiple lines of treatment</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566499-4000px.png">(PO3-20-08) Case Studies on Detecting Ductal Carcinoma in Situ Using Contrast-Enhanced Spectral Mammography and Predictive Indicators for Underestimation</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566960-4000px.png">(PO3-20-09) METACHRONOUS METAPLASTIC BREAST CARCINOMA IN A 55-YEAR-OLD PATIENT WITH SEROUS OVARIAN CARCINOMA</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566985-4000px.png">(PO3-20-10) Case Series: Invasive Secretory Carcinoma</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567059-4000px.png">(PO3-20-12) A Case Report on the Management of a Patient with Local Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566657-4000px.png">(PO3-22-02) Concurrent chemotherapy with adjuvant radiation for patients with high-risk locally advanced breast cancer: safety and outcomes</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566772-4000px.png">(PO3-22-03) Effect of Radiation Therapy on Survival Outcomes in Elderly ER&#x2F;PR Positive AJCC Stage T1 Breast Cancer Patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566776-4000px.png">(PO3-22-04) PMRT Decision with low prediction of genomic test score in pT3N0M0 luminal breast cancer: Protocol MF22-02: International multicenter real-world data</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567175-4000px.png">(PO3-22-05) Investigating HER2-low tumors from a locoregional perspective- a secondary analysis of a randomized radiotherapy trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567182-4000px.png">(PO3-22-06) Safety and efficacy of trastuzumab deruxtecan and concomitant radiation therapy in patients with metastatic HER2-positive breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566643-4000px.png">(PO3-22-08) Impact of Zip Code-Based Income on Reconstructive Method and Outcomes in Mutation-Positive Breast Cancer Patients</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566671-4000px.png">(PO3-22-09) Implementation of nanoparticle-assisted axillary staging: reduced axillary intervention for patients with node-positive breast cancer following neoadjuvant therapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566677-4000px.png">(PO3-22-10) 3D-CT mapping with a photo-translucent application using iPad delineates tumor lesions on patient breast skin in breast-conserving surgery: Preliminary results.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566686-4000px.png">(PO3-22-12) Clinical feasibility of nipple sparing mastectomy (NSM) followed by immediate reconstruction based on direct-to-implant technique</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566696-4000px.png">(PO3-23-01) Triple-tracer Technique for Sentinel Lymph Node Biopsy of Breast Cancer after neoadjuvant Chemotherapy using Blue-dye</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566736-4000px.png">(PO3-23-02) Delays in breast cancer surgery during the COVID-19 pandemic: A population-based analysis</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566804-4000px.png">(PO3-23-03) Radar reflectors for marking of target lymph nodes in patients receiving neoadjuvant chemotherapy for breast cancer â?a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566810-4000px.png">(PO3-23-04) Patient-reported outcomes and complication profiles of implant-based breast reconstruction in patients with postmastectomy radiation therapy</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566813-4000px.png">(PO3-23-06) Short-term clinical and patient-reported outcomes of oncoplastic breast conserving surgery and mastectomy with and without immediate breast reconstruction: The UK ANTHEM multicentre prospective cohort study</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2576718-4000px.png">(PO3-23-07) Evaluation of the role of axillary ultrasound to estimate axillary nodal burden to guide de-escalation of upfront axillary surgery in node positive early breast cancer patients.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566983-4000px.png">(PO3-23-08) Cancer and immune cells evolutionary trajectories under treatment with the aromatase inhibitor letrozole and the CDK4&#x2F;6 inhibitor ribociclib.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566992-4000px.png">(PO3-23-09) ESR1 mutations drive resistance to CDK4&#x2F;6 inhibitors in ER+ Breast Cancer.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566509-4000px.png">(PO3-23-10) Continued treatment with CDK4&#x2F;6 inhibitors slow tumor progression by extending G1-phase duration in drug resistant populations.</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567151-4000px.png">(PO3-23-11) Multiomics analysis of ER+ breast cancer with matched primaries</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2566860-4000px.png">(PO3-24-01) Mapping inter- and intra-tumor heterogeneity in Ductal Carcinoma in situ and invasive breast cancer using integrative multi-omic profiling</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567003-4000px.png">(PO3-24-02) Molecular characterization and therapeutic approach for VISTA+ triple-negative breast cancers</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567037-4000px.png">(PO3-24-03) Cisplatin synergizes immune checkpoint blocking through RNFT1 mediated PD-L1 recycling in Triple Negative Breast Cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567058-4000px.png">(PO3-24-04) Altered epigenetic modifications and genome architecture reshape lipid metabolism during secondary trastuzumab resistance formation of HER2-positive breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567065-4000px.png">(PO3-24-05) Cysteine metabolism related ferroptosis sensitivity in trastuzumab resistant HER2 positive breast cancer</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567072-4000px.png">(PO3-24-06) Integrative genomic and CRISPR screen analysis identifies synthetic viability interactions in BRCA1&#x2F;2 cancers</a><br><a target="_blank" rel="noopener" href="https://1fb872b80d3df585b41f-41f06c41ae393ec809a826abae176f86.ssl.cf1.rackcdn.com//2567161-4000px.png">(PO3-24-07) The role of Hepatitis A Virus Cellular Receptor 1 (HAVCR1) in breast cancer and the impact on penetration of blood brain barrier</a></p></div><footer class="article-footer"><a data-url="https://en.medlish.eu.org/2023/12/07/2023-sabcs-poster/" data-id="clpux6oic0000zkke5wzeh7mm" data-title="2023 sabcs poster" class="article-share-link"><span class="fa fa-share">分享</span></a></footer></div><nav id="article-nav"><a href="/2023/10/22/Evolving-frontline-treatment-paradigms/" id="article-nav-older" class="article-nav-link-wrap"><strong class="article-nav-caption">后一篇</strong><div class="article-nav-title">Evolving frontline treatment paradigms</div></a></nav></article></section><aside id="sidebar"><div class="widget-wrap"><h3 class="widget-title">分类</h3><div class="widget"><ul class="category-list"><li class="category-list-item"><a class="category-list-link" href="/categories/2023SABCS/">2023SABCS</a></li></ul></div></div><div class="widget-wrap"><h3 class="widget-title">标签</h3><div class="widget"><ul class="tag-list" itemprop="keywords"><li class="tag-list-item"><a class="tag-list-link" href="/tags/ESMO2023/" rel="tag">ESMO2023</a></li></ul></div></div><div class="widget-wrap"><h3 class="widget-title">标签云</h3><div class="widget tagcloud"><a href="/tags/ESMO2023/" style="font-size:10px">ESMO2023</a></div></div><div class="widget-wrap"><h3 class="widget-title">归档</h3><div class="widget"><ul class="archive-list"><li class="archive-list-item"><a class="archive-list-link" href="/archives/2023/12/">十二月 2023</a></li><li class="archive-list-item"><a class="archive-list-link" href="/archives/2023/10/">十月 2023</a></li></ul></div></div><div class="widget-wrap"><h3 class="widget-title">最新文章</h3><div class="widget"><ul><li><a href="/2023/12/07/2023-sabcs-poster/">2023 sabcs poster</a></li><li><a href="/2023/10/22/Evolving-frontline-treatment-paradigms/">Evolving frontline treatment paradigms</a></li></ul></div></div></aside></div><footer id="footer"><div class="outer"><div id="footer-info" class="inner">&copy; 2023 Lucas Fu<br>Powered by <a href="https://hexo.io/" target="_blank">Hexo</a></div></div></footer></div><nav id="mobile-nav"><a href="/" class="mobile-nav-link">Home</a> <a href="/archives" class="mobile-nav-link">Archives</a></nav><script src="/js/jquery-3.6.4.min.js"></script><script src="/fancybox/jquery.fancybox.min.js"></script><script src="/js/script.js"></script></div></body></html>